MCID: LFR001
MIFTS: 79

Li-Fraumeni Syndrome malady

Categories: Genetic diseases, Rare diseases, Reproductive diseases, Neuronal diseases, Endocrine diseases, Cancer diseases

Aliases & Classifications for Li-Fraumeni Syndrome

About this section
Sources:
50OMIM, 11Disease Ontology, 69Wikipedia, 22GeneReviews, 46NIH Rare Diseases, 23GeneTests, 24Genetics Home Reference, 13DISEASES, 52Orphanet, 68UniProtKB/Swiss-Prot, 25GTR, 12diseasecard, 48Novoseek, 36MedlinePlus, 37MeSH, 66UMLS, 43NCIt, 29ICD10 via Orphanet, 38MESH via Orphanet, 67UMLS via Orphanet, 35MedGen, 28ICD10, 60SNOMED-CT, 62The Human Phenotype Ontology
See all MalaCards sources

Aliases & Descriptions for Li-Fraumeni Syndrome:

Name: Li-Fraumeni Syndrome 50 11 69 22 46 23 24 13 52 68 12 48 37 66
Sbla Syndrome 11 22 46 23 24
Sarcoma Family Syndrome of Li and Fraumeni 46 24
Li-Fraumeni Syndrome 2 68 25
Li-Fraumeni Syndrome 1 25 66
Li Fraumeni Syndrome 46 25
Breast Diseases 48 36
Sarcoma 22 66
Breast 22 25
 
Lfs 24 68
Sarcoma, Breast, Leukemia, and Adrenal Gland Syndrome 24
Sarcoma, Breast, Leukaemia and Adrenal Gland Syndrome 11
Li-Fraumeni Familiar Cancer Susceptibility Syndrome 11
Leukemia,adrenal Gland 22
Sarcoma - Category 66
Lfs2 68
Lfs1 46

Characteristics:

Orphanet epidemiological data:

52
li-fraumeni syndrome:
Inheritance: Autosomal dominant; Prevalence: 1-9/100000 (United Kingdom),1-9/100000 (United States); Age of onset: All ages; Age of death: any age

HPO:

62


Classifications:



External Ids:

Disease Ontology11 DOID:3012
MeSH37 D016864
NCIt43 C3476
Orphanet52 ORPHA524
SNOMED-CT60 428850001
ICD10 via Orphanet29 D48.9
MESH via Orphanet38 D016864
UMLS via Orphanet67 C0085390

Summaries for Li-Fraumeni Syndrome

About this section
UniProtKB/Swiss-Prot:68 Li-Fraumeni syndrome: Autosomal dominant familial cancer syndrome that in its classic form is defined by the existence of a proband affected by a sarcoma before 45 years with a first degree relative affected by any tumor before 45 years and another first degree relative with any tumor before 45 years or a sarcoma at any age. Other clinical definitions for LFS have been proposed (PubMed:8118819 and PubMed:8718514) and called Li-Fraumeni like syndrome (LFL). In these families affected relatives develop a diverse set of malignancies at unusually early ages. Four types of cancers account for 80% of tumors occurring in TP53 germline mutation carriers: breast cancers, soft tissue and bone sarcomas, brain tumors (astrocytomas) and adrenocortical carcinomas. Less frequent tumors include choroid plexus carcinoma or papilloma before the age of 15, rhabdomyosarcoma before the age of 5, leukemia, Wilms tumor, malignant phyllodes tumor, colorectal and gastric cancers. Li-Fraumeni syndrome 2: A highly penetrant familial cancer syndrome that in its classic form is defined by the existence of a proband affected by a sarcoma before 45 years with a first degree relative affected by any tumor before 45 years and another first degree relative with any tumor before 45 years or a sarcoma at any age. Other clinical definitions for LFS have been proposed (PubMed:8118819 and PubMed:8718514) and called Li-Fraumeni like syndrome (LFL). In these families affected relatives develop a diverse set of malignancies at unusually early ages. Four types of cancers account for 80% of tumors occurring in TP53 germline mutation carriers: breast cancers, soft tissue and bone sarcomas, brain tumors (astrocytomas) and adrenocortical carcinomas. Less frequent tumors include choroid plexus carcinoma or papilloma before the age of 15, rhabdomyosarcoma before the age of 5, leukemia, Wilms tumor, malignant phyllodes tumor, colorectal and gastric cancers.

MalaCards based summary: Li-Fraumeni Syndrome, also known as sbla syndrome, is related to gastric cancer and leiomyosarcoma, and has symptoms including acute leukemia, lymphoma and neoplasm of the pancreas. An important gene associated with Li-Fraumeni Syndrome is TP53 (Tumor Protein P53), and among its related pathways are DNA Damage Induced 14-3-3Sigma Signaling and p53 pathway (Pathway Interaction Database). The drugs thiotepa and ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include breast, bone and lymph node, and related mouse phenotypes are pigmentation and liver/biliary system.

Disease Ontology:11 An autosomal dominant disease characterized by increases risk of developing several types of cancer, including breast cancer, osteosarcomata and soft tissue sarcomata.

NIH Rare Diseases:46 Li-fraumeni syndrome (lfs) is an inherited condition that is characterized by an increased risk for certain types of cancer. affected people often develop cancer at an earlier age than expected and may be diagnosed with more than one cancer during their lifetime. lfs is primarily associated with sarcomas (cancers of muscle, bone or connective tissue), breast cancer, brain tumors, leukemia and adrenocortical carcinoma; however, many other types of cancer have been reported in people with this condition. it is caused by changes (mutations) in the tp53 gene and is inherited in an autosomal dominant manner. management may include high-risk cancer screening and/or prophylactic surgeries. last updated: 5/4/2015

MedlinePlus:36 Most women experience breast changes at some time. your age, hormone levels, and medicines you take may cause lumps, bumps, and discharges (fluids that are not breast milk). if you have a breast lump, pain, discharge or skin irritation, see your health care provider. minor and serious breast problems have similar symptoms. although many women fear cancer, most breast problems are not cancer. some common breast changes are fibrocystic breast changes - lumpiness, thickening and swelling, often just before a woman's period cysts - fluid-filled lumps fibroadenomas - solid, round, rubbery lumps that move easily when pushed, occurring most in younger women intraductal papillomas - growths similar to warts near the nipple blocked milk ducts milk production when a woman is not breastfeeding nih: national cancer institute

Genetics Home Reference:24 Li-Fraumeni syndrome is a rare disorder that greatly increases the risk of developing several types of cancer, particularly in children and young adults.

OMIM:50 Li-Fraumeni syndrome (LFS) is a clinically and genetically heterogeneous inherited cancer syndrome. LFS is... (151623) more...

Wikipedia:69 Li–Fraumeni syndrome is a rare cancer predisposition hereditary disorder characterized as autosomal... more...

Description from OMIM:50 609265

GeneReviews summary for NBK1311

Related Diseases for Li-Fraumeni Syndrome

About this section

Diseases in the Li-Fraumeni Syndrome family:

Li-Fraumeni Syndrome 3 Li-Fraumeni Syndrome, Chek2-Related

Diseases related to Li-Fraumeni Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 219)
idRelated DiseaseScoreTop Affiliating Genes
1gastric cancer31.5BCL2, CDKN2A, TP53
2leiomyosarcoma30.8BRCA1, BRCA2, TP53
3adrenal cortical carcinoma30.0BAX, BCL2, CDKN2A, EGFR, PIK3CA, TP53
4gliosarcoma29.7CDKN1A, CDKN2A, EGFR, IDH1, MDM2, PTEN
5lung cancer26.5ATM, BAX, BCL2, CAV1, CDKN1A, CDKN2A
6prostate cancer25.9ATM, BAX, BCL2, BRCA1, BRCA2, CAV1
7colorectal cancer24.9BAX, BCL2, BRCA1, BRCA2, CAV1, CDKN1A
8breast cancer24.5ATM, BAX, BCL2, BRCA1, BRCA2, CAV1
9kaposi sarcoma12.5
10li-fraumeni syndrome 312.4
11li-fraumeni syndrome, chek2-related12.4
12breast disease12.2
13lujan syndrome11.3
14lassa fever11.3
15mastitis11.1
16liddle syndrome, scnn1g-related10.9CHEK2, TP53
17salivary gland adenoid cystic carcinoma10.9CDKN2A, TP53
18chromosome 7p duplication10.9MDM2, TP53
19biliary papillomatosis10.9CDKN2A, TP53
20glioblastoma10.8
21karak syndrome10.8CDKN2A, PTEN
22epidural spinal canal angiolipoma10.7CDKN2A, MDM2
23microglandular adenosis10.7
24diabetic mastopathy10.7
25esophagus verrucous carcinoma10.7CDKN2A, PTEN, TP53
26pleuropulmonary blastoma type 210.7CDKN2A, MDM2, PTEN
27peptic ulcer disease10.7EGFR, TP53
28pasli disease10.7MDM2, TP53
29vulvar sebaceous carcinoma10.7CDKN1A, MDM2, TP53
30x-linked congenital generalized hypertrichosis10.7BCL2, CDKN2A, TP53
31cystinosis, nephropathic10.7IDH1, TP53
32maxillary sinus squamous cell carcinoma10.7IDH1, TP53
33split hand split foot malformation autosomal recessive10.7CDKN2A, TP53
34spinal cord glioma10.7IDH1, MDM2, TP53
35periodontal disease10.7CDKN2A, MDM2, TP53
36fallopian tube adenosarcoma10.7CDKN2A, MDM2, TP53
37congenital pulmonary veins atresia or stenosis10.7BRCA1, BRCA2
38localized chondrosarcoma10.7CDKN2A, IDH1, MDM2
39pseudoangiomatous stromal hyperplasia10.7PIK3CA, TP53
40mild phosphoribosylpyrophosphate synthetase superactivity10.6BCL2, CDKN1A, CDKN2A
41adult teratoma10.6BAX, BCL2, TP53
42pylorus cancer10.6BAX, BCL2, TP53
43melanotic medulloblastoma10.6IDH1, MDM2, PTEN
44interstitial myocarditis10.6PIK3CA, PTEN
45prostate cancer, hereditary, x-linked 110.6CDKN1A, PTEN, TP53
46herpes simplex10.6CDKN2A, EGFR, TP53
47dubin-johnson syndrome10.6CDKN2A, PTEN, TP53
48anal squamous cell carcinoma10.6CDKN2A, EGFR, TP53
49bladder verrucous squamous cell carcinoma10.6CDKN1A, CDKN2A, MDM2, TP53
50bilateral retinoblastoma10.6CDKN1A, CDKN2A, MDM2, TP53

Graphical network of the top 20 diseases related to Li-Fraumeni Syndrome:



Diseases related to li-fraumeni syndrome

Symptoms for Li-Fraumeni Syndrome

About this section

Symptoms by clinical synopsis from OMIM:

151623

Clinical features from OMIM:

151623,609265

Symptoms:

 52 (show all 12)
  • progressive encephalopathy
  • neoplasm
  • lymphoma
  • osteosarcoma
  • melanoma
  • neoplasm of the pancreas
  • breast carcinoma
  • neoplasm of the nervous system
  • neoplasm of the skin
  • sarcoma
  • neoplasm of the colon
  • neoplasm of the adrenal cortex

HPO human phenotypes related to Li-Fraumeni Syndrome:

(show all 27)
id Description Frequency HPO Source Accession
1 acute leukemia hallmark (90%) HP:0002488
2 lymphoma hallmark (90%) HP:0002665
3 neoplasm of the pancreas hallmark (90%) HP:0002894
4 neoplasm of the nervous system hallmark (90%) HP:0004375
5 neoplasm of the skin hallmark (90%) HP:0008069
6 neoplasm of the skeletal system hallmark (90%) HP:0010622
7 neoplasm of the breast hallmark (90%) HP:0100013
8 sarcoma hallmark (90%) HP:0100242
9 neoplasm of the colon hallmark (90%) HP:0100273
10 neoplasm of the adrenal cortex hallmark (90%) HP:0100641
11 melanoma occasional (7.5%) HP:0002861
12 neoplasm of the lung occasional (7.5%) HP:0100526
13 acute leukemia HP:0002488
14 nephroblastoma HP:0002667
15 osteosarcoma HP:0002669
16 neoplasm of the pancreas HP:0002894
17 breast carcinoma HP:0003002
18 colon cancer HP:0003003
19 adrenocortical carcinoma HP:0006744
20 prostate cancer HP:0012125
21 lung adenocarcinoma HP:0030078
22 soft tissue sarcoma HP:0030448
23 prostate neoplasm HP:0100787
24 meningioma HP:0002858
25 glioma HP:0009733
26 stomach cancer HP:0012126
27 sarcoma HP:0100242

Drugs & Therapeutics for Li-Fraumeni Syndrome

About this section

Drugs for Li-Fraumeni Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 492)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
LapatinibApproved March 2007Phase 4, Phase 3, Phase 2, Phase 1, Phase 0296231277-92-2, 388082-78-8208908, 9941095
Synonyms:
1xkk
231277-92-2
388082-78-8
4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline
AB1004631
AC-1314
AC1L4LL4
AKOS005145766
CHEBI:49603
CHEMBL1201179
CHEMBL554
CID11557040
CID208908
D04024
D08108
DB01259
DB02584
EN002712
FMM
GSK 572016
GSK572016
GW 572016
GW 572016X
GW-2016
GW-572016
GW-572016F
GW2016
GW572016
HMS2089H10
I01-1247
 
Kinome_3684
Kinome_3685
LAPATINIB DITOSYLATE MONOHYDRATE
LS-187029
LS-187771
Lapatinib
Lapatinib (INN)
Lapatinib Ditosylate
Lapatinib [INN]
Lapatinib ditosylate
Lapatinib ditosylate (USAN)
Lapatinib tosilate hydrate
Lapatinib tosilate hydrate (JAN)
Lapatinib, Tykerb, GW572016
N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine
N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine
N-(3-chloro-4-((3-Fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine
N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE
N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine
NCGC00167507-01
NSC745750
TL80090051
Tycerb
Tykerb
Tykerb (TN)
Tyverb
UNII-0VUA21238F
lapatinib
lapatinib ditosylate
nchembio866-comp20
2
DoxilApproved June 1999Phase 4, Phase 3, Phase 2, Phase 1167631703
Synonyms:
Dox-SL
Doxil
 
Evacet
LipoDox
Pegylated Liposomal Doxorubicin Hydrochloride
liposomal doxorubicin
3
DocetaxelApproved May 1996Phase 4, Phase 3, Phase 2, Phase 1, Phase 01880114977-28-5148124, 9877265
Synonyms:
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate
(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
01885_FLUKA
114977-28-5
4-(Acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
AC-383
AC1L3WHJ
ANX-514
BIND-014
C11231
CHEBI:4672
CHEMBL92
CID148124
D07866
DB01248
Docetaxel
Docetaxel (INN)
Docetaxel anhydrous
Docetaxel, Trihydrate
EmDOC
 
HMS2089K08
InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,5
MolPort-003-847-005
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-Boc-10-deacetyl taxol
NSC-628503
PSMA-targeted docetaxel nanoparticle
RP-56976
SDP-014
TXL
Taxotere
Taxotere (TN)
Taxotere(R)
XRP-6976L
docetaxel
docetaxel 114977-28-5
nchembio.188-comp8
nchembio.2007.34-comp7
nchembio.573-comp11
nchembio853-comp8
4
CapecitabinePhase 4, Phase 3, Phase 2, Phase 11257154361-50-960953
Synonyms:
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
154361-50-9
158798-73-3
5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine
5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine
AC1L1U83
AC1Q4KU8
Ambap154361-50-9
C110904
C12650
C15H22FN3O6
CAPE
CAPECITABINE
CHEBI:31348
CHEMBL1773
CID60953
Capecitabin
Capecitabina
Capecitabine (JAN/USAN/INN)
Capecitabine [USAN]
Capecitabinum
Capecitibine
Capiibine
Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester
Caxeta
 
D01223
DB01101
FT-0082472
HSDB 7656
LS-59070
MolPort-005-938-254
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
R-340
R340
RG-340
Ro 09-1978
Ro 09-1978/000
Ro-09-1978
Ro-09-1978/000
S1156_Selleck
UNII-6804DJ8Z9U
Xabine
Xeloda
Xeloda (TN)
Xeloda, Captabin, Capecitabine
ZINC03806413
capecitabina
capecitabine
capecitabinum
pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate
5
IsofluranePhase 415626675-46-73763
Synonyms:
1-Chloro-2,2,2-trifluoroethyl difluoromethyl ether
1-chloro-2,2,2-Trifluoroethyl difluoromethyl ether
2-Chloro-2-(difluoromethoxy)-1,1,1-trifluoroethane
2-chloro-2-difluoromethoxy-1,1,1-trifluoroethane
26675-46-7
AC-154802
AC1L1GNN
AErrane (Veterinary)
Aerrane
BRN 1852087
C07518
CCRIS 3043
CHEBI:6015
CHEMBL1256
CID3763
Compound 469
D00545
D007530
DB00753
EINECS 247-897-7
Ethane
Ether, 1-chloro-2,2,2-trifluoroethyl difluoromethyl
 
Forane
Forane (TN)
Forene
I14-1303
IsoFlo
Isoflurane
Isoflurane (JP15/USP/INN)
Isoflurane [Anaesthetics, volatile]
Isoflurane [USAN:BAN:INN:JAN]
Isoflurane [USAN:INN:BAN:JAN]
Isoflurane [Usan:Ban:Inn:Jan]
Isoflurano
Isoflurano [INN-Spanish]
Isofluranum
Isofluranum [INN-Latin]
Jsp005223
LS-7462
MolPort-000-153-606
NCGC00181037-01
R-E 235dal
ST51041445
UNII-CYS9AKD70P
isoflurane
6Imatinib MesylatePhase 4, Phase 2, Phase 1588123596
7
SevofluranePhase 4, Phase 3, Phase 245328523-86-65206
Synonyms:
1,1,1,3,3,3-Hexafluoro-2-(fluoromethoxy)propane
28523-86-6
AC-15484
AC1L1JU0
BRN 2041023
Bax 3084
C009250
C07520
C4H3F7O
CHEBI:9130
CHEMBL1200694
CID5206
D00547
DB01236
F0691
Fluoromethyl 1,1,1,3,3,3-Hexafluoroisopropyl Ether
Fluoromethyl 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether
I14-13357
LS-67851
MR6S4
 
MR_6S4
MolPort-001-775-746
NCGC00167421-01
PC4681
Sevofluran
Sevoflurane
Sevoflurane (JAN/USAN/INN)
Sevoflurane [USAN:INN:BAN:JAN]
Sevoflurano
Sevoflurano [INN-Spanish]
Sevofluranum
Sevofluranum [INN-Latin]
Sevofrane
Sevorane
Sojourn
UNII-38LVP0K73A
Ultane
Ultane (TN)
ZINC01530810
fluoromethyl hexafluoroisopropyl ether
fluoromethyl-2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether
sevoflurane
8
VinorelbinePhase 4, Phase 3, Phase 2, Phase 1, Phase 035871486-22-160780, 44424639
Synonyms:
5'-Noranhydrovinblastine
71486-22-1
AC1L1KVK
AC1L1TWQ
AC1L75Q4
ANX-530
Ambap71486-22-1
BIDD:PXR0186
C45H54N4O8
CHEBI:480999
CHEMBL607994
CID355119
CID5311497
CID5672
CID60780
CID6426842
D08680
DB00361
Eunades
Exelbine
HMS2090E13
HSDB 7665
I06-0084
I06-0085
KW 2307
KW 2307 base
KW-2307
 
LS-97533
MolPort-006-822-661
MolPort-006-823-869
NCGC00165966-02
NVB
Navelbine
Navelbine (TN)
Navelbine Base
Navelbine base
Nor-5'-anhydrovinblastine
SDP-012
UNII-Q6C979R91Y
Vinorelbin
Vinorelbina
Vinorelbina [Spanish]
Vinorelbine
Vinorelbine (INN)
Vinorelbine Bitartrate
Vinorelbine Ditartarate
Vinorelbine Ditartrate
Vinorelbine Tartrate
Vinorelbine [INN:BAN]
Vinorelbine ditartrate
Vinorelbine tartrate
Vinorelbinum
Vinorelbinum [Latin]
methyl (2b,3b,4b,5a,12b,19a)-4-(acetyloxy)-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate
methyl (2beta,3beta,4beta,5alpha,12beta,19alpha)-4-acetoxy-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate
vinorelbine
9cadexomer iodinePhase 4, Phase 3, Phase 1484
10
Etidronic acidPhase 4, Phase 3827414-83-7, 2809-21-43305
Synonyms:
(1-Hydroxyethylene)diphosphonic acid
(1-Hydroxyethylidene)bis(phosphonic acid)
(1-Hydroxyethylidene)bisphosphonic acid
(1-Hydroxyethylidene)diphoshonic acid
(1-Hydroxyethylidene)diphosphonic acid
(1-hydroxy-1-phosphonoethyl)phosphonic acid
(1-hydroxy-ethylidene)diphosphonic acid
(1-hydroxyethane-1,1-diyl)bis(phosphonic acid)
(Hydroxyethylidene)diphosphonic acid
0-02-00-00171 (Beilstein Handbook Reference)
1,1,1-Ethanetriol diphosphonate
1-HYDROXY-1,1-DIPHOSPHONOETHANE
1-Hydroxy-1,1-diphosphonoethane
1-Hydroxyethane-1,1,-diphosphonic acid
1-Hydroxyethane-1,1-bisphosphonic acid
1-Hydroxyethane-1,1-diphosphonate
1-Hydroxyethane-1,1-diphosphonic acid
1-Hydroxyethanediphosphonic acid
1-Hydroxyethylidene 1,1-diphosphonic acid
1-Hydroxyethylidene-1,1-biphosphonate
1-Hydroxyethylidene-1,1-bisphosphonate
1-Hydroxyethylidene-1,1-diphosphonic acid
1-Hydroxyethylidenediphosphonic acid
1-hydroxyethane 1,1-diphosphonic acid
1000SL
100511-44-2
103736-66-9
106908-76-3
129130-42-3
138360-84-6
14860-53-8 (tetra-potassium salt)
192526-55-9
2809-21-4
303177-33-5
51888-66-5
54342_ALDRICH
54342_FLUKA
66216-98-6
853028-38-3
85985-26-8
86159-18-4
AC1L1FMT
Acetodiphosphonic acid
Acide etidronique
Acide etidronique [INN-French]
Acido etidronico
Acido etidronico [INN-Spanish]
Acidum etidronicum
Acidum etidronicum [INN-Latin]
BPBio1_000997
BRN 1789291
BSPBio_000905
Bio-0708
C07736
CHEBI:170675
CHEBI:4907
CHEMBL871
CID3305
 
Cintichem Technetium 99m Hedspa
D02373
DB01077
Dequest 2010
Dequest 2015
Dequest Z 010
Didronel
Didronel IV
Diphosphonate (base)
EHDP
EINECS 220-552-8
Ethane-1-hydroxy-1,1-bisphosphonate
Ethane-1-hydroxy-1,1-bisphosphonic acid
Ethane-1-hydroxy-1,1-diphosphonate
Ethane-1-hydroxy-1,1-diphosphonic acid
Etidronate
Etidronate Disodium
Etidronic acid
Etidronic acid (USAN/INN)
Etidronic acid [USAN:INN:BAN]
Etidronic acid monohydrate
Etidronsaeure
Etidronsäure
Ferrofos 510
H0587
H6773_ALDRICH
H6773_SIGMA
HEDP
HSDB 5898
Hydroxyethane-1,1-diphosphonic acid
Hydroxyethanediphosphonic acid
I14-1271
Jsp005415
LS-106637
MLS002207267
MLS002695948
MPI Stannous Diphosphonate
MolPort-001-786-542
NCGC00159352-02
NSC 227995
NSC227995
Osteoscan
Oxyethylidenediphosphonic acid
Phosphonic acid, 1-hydroxy-1,1-ethanediyl ester
Prestwick0_000863
Prestwick1_000863
Prestwick2_000863
Prestwick3_000863
RP 61
SMR000038750
SPBio_002826
STK721995
Turpinal SL
UNII-M2F465ROXU
acide étidronique
acidum etidronicum
ethane-1-hydroxy-1,1-bisphosphonic acid
etidronate
ácido etidrónico
11
VinblastinePhase 4, Phase 3, Phase 2, Phase 1, Phase 0398865-21-413342, 241903
Synonyms:
(2ALPHA,2'BETA,3BETA,4ALPHA,5BETA)-VINCALEUKOBLASTINE
(2alpha,2'BETA,3beta,4alpha,5beta)-vincaleukoblastine
(2xi,3beta,4'beta,19xi)-vincaleukoblastine
(3aR-(3aalpha,4beta,5beta,5abeta,9(3R*,5S*,7R*,9S*),10bR*,13aalpha))-methyl 4-(acetyloxy)-3a-ethyl-9-(5-ethyl-1,4,5,6,7,8,9,10-octahydro-5-hydroxy-9-(methoxycarbonyl)-2H-3,7-methanoazacycloundecino(5,4-b)indol-9-yl)-3a,4,5,5a,6,11,12,13a-octahydro-5-hydroxy-8-methoxy-6-methyl-1H-indolizino(8,1-cd)carbazole-5-carboxylate
143-67-9
1z2b
29060-LE
865-21-4
AC-20335
AC1L21JC
AC1L68D2
AC1MXZJ2
BIDD:PXR0201
BRD-K01188359-065-02-5
BSPBio_001228
BSPBio_003594
Bio-0111
C07201
C46H58N4O9
CCRIS 9002
CHEBI:171516
CHEBI:27375
CHEMBL159
CHEMBL607706
CID13342
CID241903
CID3823887
CID6710780
D08675
DB00570
EINECS 212-734-0
HMS2090K05
HSDB 3263
KBio3_003033
LS-1859
LS-187263
 
MolPort-002-518-262
MolPort-005-910-359
NCGC00022585-04
NCGC00181127-01
NCI-C04842
NCI60_004200
NChemBio.2007.10-comp22
NDC 0002-1452-01
NSC 47842
Neuro_000020
Nincaluicolflastine
Rozevin
SPBio_000680
STOCK1N-38480
Spectrum2_000890
Spectrum3_001994
UNII-5V9KLZ54CY
VLB
VR-8
Velban
Velbe
Vinblastin
Vinblastina
Vinblastina (TN)
Vinblastina [DCIT]
Vinblastina [Dcit]
Vinblastine
Vinblastine (INN)
Vinblastine Sulfate
Vinblastine [INN:BAN]
Vinblastinum
Vinblastinum [INN-Latin]
Vincaleucoblastin
Vincaleucoblastine
Vincaleukoblastine
Vincoblastine
nchembio873-comp22
vinblastine
12
SulbactamPhase 43268373-14-8
Synonyms:
(2S,5R)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide
 
Sulbactam Benzathine
penicillanic acid 1,1-dioxide
penicillanic acid sulfone
13
LetrozolePhase 4, Phase 3, Phase 2, Phase 1, Phase 0368112809-51-53902
Synonyms:
1-[Bis-(4-cyanophenyl)methyl]-1,2,4-triazole
1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole
112809-51-5
4,4'-((1h-1,2,4-triazol-1-yl)methylene)dibenzonitrile
4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile
4,4'-(1H-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile)
4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile
4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-Benzonitrile Letrozole
4,4'-(1h-1,2,4-triazol-1-ylmethylene) bis-benzonitrile
4,4'-(1h-1,2,4-triazol-1-ylmethylene)bis-benzonitrile
4,4'-(1h-1,2,4-triazol-1-ylmethylene)bisbenzonitrile
4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile
AB00514009
AC-1193
AC1L1GYT
AKOS005145822
BIDD:GT0015
BIDD:PXR0130
BPBio1_001331
BRD-K88789588-001-03-2
BSPBio_001209
Bio-0057
C067431
C08163
C17H11N5
CAS-112809-51-5
CCRIS 8822
CGS 20267
CGS 20267, Femara, Piroxicam, Letrozole
CGS-20267
CHEBI:6413
CHEMBL1444
CID3902
CPD000466343
D00964
 
DB01006
FEM-345
Femara
Femara (TN)
Femera
HMS1571M11
HMS2051E08
HMS2089L22
HSDB 7461
I06-0022
LS-38788
Letoval
Letrozol
Letrozole
Letrozole (JAN/USP/INN)
Letrozole [USAN:INN]
MLS000759455
MLS001424038
MLS002584991
MolPort-003-848-373
NCGC00016973-01
NCGC00016973-02
NSC719345
Novartis Brand of Letrozole
Prestwick0_001025
Prestwick1_001025
Prestwick2_001025
Prestwick3_001025
S1235_Selleck
SAM001246649
SMR000466343
SPBio_003070
TL8000371
UNII-7LKK855W8I
ZINC03778874
letrozole
14
FluorouracilPhase 4, Phase 3, Phase 2, Phase 1172851-21-83385
Synonyms:
1-fluoro-1h-pyrimidine-2,4-dione
1004-03-1
1upf
2,4-Dihydroxy-5-fluoropyrimidine
2,4-Dioxo-5-fluoropryimidine
2,4-Dioxo-5-fluoropyrimidine
47576_FLUKA
4921-97-5
5 FU Lederle
5 FU medac
5 Fluorouracil
5 Fluorouracil biosyn
5 HU Hexal
5-FU
5-FU (TN)
5-FU Lederle
5-FU medac
5-Faracil
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol
5-Fluor-2,4-pyrimidindiol [Czech]
5-Fluoracil
5-Fluoracil [German]
5-Fluoracyl
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-Fluoro-2,4-pyrimidinedione
5-Fluoropyrimidin-2,4-diol
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluoruracil
5-Fluoruracil [German]
5-Fluracil
5-Ftouracyl
5-HU Hexal
5-fluoro uracil
5-fluoro-1H-pyrimidine-2,4-dione
5-fluoropyrimidine-2,4(1H,3H)-dione
5-fluorouracil
51-21-8
5FU
79108-01-3
AC-11201
AC1L1FTE
AC1Q4N2X
AI3-25297
AKOS000119162
AKOS003237897
AccuSite
Actino-Hermal
Adrucil
Adrucil (TN)
Allergan Brand of Fluorouracil
Arumel
BB_NC-0576
BSPBio_002048
C07649
C4H3FN2O2
CCRIS 2582
CHEBI:46345
CHEMBL185
CID3385
CPD0-1327
CPD000038082
CSP Brand of Fluorouracil
Carac
Carac (TN)
Carzonal
Cinco FU
Cytosafe
D005472
D00584
DB00544
Dakota Brand of Fluorouracil
Dakota, Fluorouracile
Dermatech Brand of Fluorouracil
Dermik Brand of Fluorouracil
DivK1c_000054
EINECS 200-085-6
EU-0100536
Effluderm
Effluderm (free base)
Efudex
Efudix
Efurix
F 6627
F0151
F6627_SIGMA
F8423_SIGMA
FT-0082524
FU
Ferrer Brand of Fluorouracil
Fiverocil
Fluoro Uracil
Fluoro Uracile ICN
Fluoro-Uracile ICN
Fluoro-uracile
Fluoro-uracilo
Fluoroblastin
Fluoroplex
Fluoroplex (TN)
Fluorouracil
Fluorouracil (JP15/USP/INN)
Fluorouracil GRY
Fluorouracil Mononitrate
Fluorouracil Monopotassium Salt
Fluorouracil Monosodium Salt
Fluorouracil Potassium Salt
Fluorouracil Teva Brand
Fluorouracil [USAN:INN:BAN:JAN]
 
Fluorouracil-GRY
Fluorouracile
Fluorouracile Dakota
Fluorouracile [DCIT]
Fluorouracilo
Fluorouracilo Ferrer Far
Fluorouracilo [INN-Spanish]
Fluorouracilum
Fluorouracilum [INN-Latin]
Fluoruracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluracilum
Fluri
Fluril
Fluro Uracil
Fluroblastin
Flurodex
Flurouracil
Flurox
Ftoruracil
Gry Brand of Fluorouracil
HMS1920O18
HMS2090I04
HMS2091F19
HMS500C16
HSDB 3228
Haemato Brand of Fluorouracil
Haemato fu
Haemato-fu
Hexal Brand of Fluorouracil
I07-0022
ICN Brand of Fluorouracil
IDI1_000054
IN1335
KBio1_000054
KBio2_001321
KBio2_003889
KBio2_006457
KBio3_001268
KBioGR_001253
KBioSS_001321
Kecimeton
LS-153
Lopac-F-6627
Lopac0_000536
MLS000069498
MLS002415705
MolPort-000-156-102
MolPort-003-990-447
MolPort-004-758-143
MolPort-004-758-144
MolPort-005-861-486
NCGC00015442-01
NCGC00015442-03
NCGC00015442-10
NCGC00091349-01
NCGC00091349-02
NCGC00091349-03
NCGC00091349-04
NCGC00091349-05
NCGC00091349-07
NCGC00091349-08
NCI60_001652
NINDS_000054
NSC 19893
NSC-19893
NSC19893
Neocorp Brand of Fluorouracil
Neofluor
Onkofluor
Onkoworks Brand of Fluorouracil
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Riemser Brand of Fluorouracil
Ro 2-9757
Ro-2-9757
Roche Brand of Fluorouracil
S1209_Selleck
SAM002264615
SMR000038082
SPBio_000291
SPECTRUM1500305
STK297802
Spectrum2_000076
Spectrum3_000434
Spectrum4_000557
Spectrum5_000718
Spectrum_000841
T5233394
TL8006093
Teva Brand of Fluorouracil
Timazin
U 8953
U-8953
UNII-U3P01618RT
UPCMLD-DP130
UPCMLD-DP130:001
URF
Ulup
WLN: T6MVMVJ EF
ZINC00897110
biosyn Brand of Fluorouracil
fluorouracil
inhibits thymilidate synthetase
medac Brand of Fluorouracil
nchembio.90-comp3
nchembio809-comp6
ribosepharm Brand of Fluorouracil
tetratogen
15
EpirubicinPhase 4, Phase 3, Phase 2, Phase 137456420-45-241867
Synonyms:
(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside
(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside
(7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione
4'-Epi-DXR
4'-Epiadriamycin
4'-Epidoxorubicin
4'-epi-DX
4'-epi-Doxorubicin
4'-epidoxorubicin
4-Epidoxorubicin
56390-09-1
56390-09-1 (hydrochloride)
56420-45-2
57918-25-9
AC1L26NP
AC1Q6JIV
BRN 1445813
C11230
C27H29NO11
CCRIS 2261
CHEBI:47898
CHEMBL417
CID41867
D07901
DB00445
Ellence
Epi-DX
Epi-Dx
Epiadriamycin
Epidoxorubicin
Epirubicin
 
Epirubicin (INN)
Epirubicin [INN:BAN]
Epirubicina
Epirubicina [INN-Spanish]
Epirubicina [Spanish]
Epirubicine
Epirubicine [French]
Epirubicine [INN-French]
Epirubicinum
Epirubicinum [INN-Latin]
Epirubicinum [Latin]
Farmorubicin (TN)
HSDB 6962
IMI 28
LS-187190
LS-93992
MLS000759412
NChemBio.2007.10-comp15
NSC 256942
NSC-256942
NSC256942
Pharmorubicin Pfs
Pidorubicin
Pidorubicina
Pidorubicina [INN-Spanish]
Pidorubicine
Pidorubicine [INN-French]
Pidorubicinum
Pidorubicinum [INN-Latin]
Ridorubicin
SMR000466308
Triferric doxorubicin
UNII-3Z8479ZZ5X
WP 697
16
ExemestanePhase 4, Phase 3, Phase 2, Phase 1203107868-30-460198
Synonyms:
(8R,9S,10R,13S,14S)-10,13-dimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione
107868-30-4
6-Methylenandrosta-1,4-diene-3,17-dione
6-Methyleneandrosta-1,4-diene-3,17-dione
6-methylideneandrosta-1,4-diene-3,17-dione
AC-2171
AC1L1SRB
AC1Q6AAZ
Ambap107868-30-4
Aromasil
Aromasin
Aromasin (TN)
Aromasin, Exemestane
Aromasine
C056516
C08162
CHEBI:4953
CHEMBL1200374
CID60198
CPD000466314
Curator_000009
D00963
DB00990
EXE
EXEMESTANE
 
Exemestance
Exemestane
Exemestane (JAN/USP/INN)
Exemestane [USAN:INN:BAN]
Exemestano
Exemestano [INN-Spanish]
Exemestanum
Exemestanum [INN-Latin]
FCE-24304
Fce 24304
HMS2051J04
HSDB 7463
LS-19329
MLS000759419
MLS001424062
MolPort-003-847-343
NSC713563
Nikidess
PNU-155971
Pfizer brand of exemestane
S1196_Selleck
S1196_Sellek
SAM001246574
SMR000466314
UNII-NY22HMQ4BX
ZINC03973334
exemestane
17
AmpicillinPhase 45469-53-46249
Synonyms:
(2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
(2S,5R,6R)-6-{[(2R)-2-amino-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
(2S,5R,6R)-6-{[(2R)-2-amino-2-phenylethanoyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
1h8s
33604-21-6
37234-64-3
47355-94-2
50584-05-9
6-(D(-)-alpha-Aminophenylacetamido)penicillanic acid
6-(D-(2-amino-2-Phenylacetamido))-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid
6-(a-Aminophenylacetamido)penicillanic acid
6-D(-)-alpha-Aminophenylacetamido-penicillanic acid
6-[(Aminophenylacetyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 9CI
69-52-3 (mono-hydrochloride salt)
69-53-4
6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carbonyl
6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carboxylic acid
7177-48-2 (TRIHYDRATE)
800-79-3
8056-87-9
96707-69-6
98520-55-9
A9393_SIGMA
AB-PC
AB-PC Sol
ABPC
AC-14075
AC1L1M46
AMP
AMPI
AMPICILLIN (SEE ALSO AMPICILLIN TRIHYDRATE 7177-48-2)
AP
AY 6108
AY 6108
AY-6108
Acillin
Adobacillin
Alpen
Amblosin
Amcill
Amfipen
Amfipen V
Amfipen v
Aminobenzylpenicillin
Amipenix S
Ampen
Ampi-Co
Ampi-Tab
Ampi-bol
Ampi-co
Ampi-tab
Ampichel
Ampicil
Ampicilina
Ampicilina [INN-Spanish]
Ampicillin
Ampicillin (USP/INN)
Ampicillin A
Ampicillin Acid
Ampicillin Anhydrate
Ampicillin Anhydrous
Ampicillin Base
Ampicillin Sodium
Ampicillin Trihydrate
Ampicillin [USAN:BAN:INN:JAN]
Ampicillin [USAN:INN:BAN:JAN]
Ampicillin [Usan:Ban:Inn:Jan]
Ampicillin acid
Ampicillin anhydrate
Ampicillina
Ampicillina [DCIT]
Ampicillina [Dcit]
Ampicilline
Ampicilline [INN-French]
Ampicillinum
Ampicillinum [INN-Latin]
Ampicin
Ampifarm
Ampikel
Ampimed
Ampipenin
Ampipenin, nt3
Ampiscel
Ampisyn
Ampivax
Ampivet
Amplacilina
Amplin
Amplipenyl
Amplisom
Amplital
Ampy-Penyl
Anhydrous Ampicillin
Anhydrous ampicillin
Anhydrous ampicillin (JP15)
Austrapen
BA 7305
BIDD:GT0184
BPBio1_000142
BRL 1341
BRL-1341
BSPBio_000128
BSPBio_001862
Bayer 5427
Binotal
Bonapicillin
Britacil
C06574
CHEBI:28971
CHEBI:53713
CHEMBL174
CID6249
Campicillin
Cimex
Copharcilin
D-(-)-6-(alpha-Aminophenylacetamido)penicillanic acid
D-(-)-6-(alpha-aminophenylacetamido)penicillanic acid
D-(-)-Ampicillin
D-(-)-alpha-Aminobenzylpenicillin
D-(-)-alpha-Aminopenicillin
D-(-)-ampicillin
D-(−)-6-(α-aminophenylacetamido)penicillanic acid
D-(−)-ampicillin
D-Ampicillin
D-Cillin
D-a-Aminobenzylpenicillin
D00204
DB00415
Delcillin
Deripen
DivK1c_000466
 
Divercillin
Doktacillin
Duphacillin
EINECS 200-709-7
Geocillin
Grampenil
Guicitrina
Guicitrine
HI 63
HMS2090I11
HSDB 3009
IDI1_000466
KBio1_000466
KBio2_000430
KBio2_002998
KBio2_005566
KBio3_001362
KBioGR_000598
KBioSS_000430
KS-R1
LS-1586
LS-169948
Lifeampil
MLS000028405
MLS001074168
Magnapen
Marcillin
MolPort-001-794-635
Morepen
NCGC00023282-05
NCGC00023282-06
NINDS_000466
NSC 528986
NSC-528986
NSC528986
Norobrittin
Novo-ampicillin
Nuvapen
OMNIPEN (AMPICILLIN)
Olin Kid
Olin kid
Omnipen
Omnipen (TN)
Omnipen-N
Orbicilina
P 50
P-50
Pen A
Pen A Oral
Pen Ampil
Pen a
Pen ampil
Penbristol
Penbritin
Penbritin paediatric
Penbritin syrup
Penbritin-S
Penbrock
Penicillin, Aminobenzyl
Penicline
Penimic
Pensyn
Pentrex
Pentrexl
Pentrexyl
Pentritin
Pfizerpen A
Pfizerpen a
Pfizerpen-A
Polycillin
Polycillin-N
Polyflex (Veterinary)
Ponecil
Prestwick0_000114
Prestwick1_000114
Prestwick2_000114
Prestwick3_000114
Princillin
Principen
Principen '125'
Principen '250'
Principen '500'
QIDamp
Qidamp
Racenacillin
Ro-Ampen
Ro-ampen
Rosampline
Roscillin
SBB063111
SK-Ampicillin
SK-ampicillin
SMP1_000211
SMR000058352
SPBio_000818
SPBio_002067
SQ 17382
Semicillin
Semicillin R
Servicillin
Spectrum2_000769
Spectrum3_000301
Spectrum4_000149
Spectrum5_000814
Spectrum_000050
Sumipanto
Supen
Synpenin
Texcillin
Tokiocillin
Tolomol
Totacillin
Totacillin (sodium)
Totacillin-N
Totalciclina
Totapen
Trifacilina
UNII-7C782967RD
Ukapen
Ultrabion
Ultrabron
Vampen
Viccillin
Viccillin S
Vidocillin
Vidopen
WY-5103
Wypicil
alpha-Aminobenzylpenicillin
ampicillanyl
ampicillin
anhydrous ampicillin
18
Nitrous oxidePhase 4, Phase 316210024-97-2948
Synonyms:
00583_FLUKA
10024-97-2
126386-65-0
129451-49-6
130835-71-1
147527-07-9
175876-44-5
295590_ALDRICH
794457-85-5
847968-13-2
850203-00-8
AC1L1ADZ
C00887
CCRIS 1225
CHEBI:17045
CHEMBL1234579
CID948
D00102
D009609
Diazyne 1-oxide
Dinitrogen monoxide
Dinitrogen oxide
Distickstoffmonoxid
E942
EINECS 233-032-0
FEMA 2779
FEMA No. 2779
Factitious air
Gas, Laughing
Gas, laughing
Gaz hilarant
HSDB 504
Hyponitrous acid anhydride
LS-7622
Lachgas
Laughing gas
N2O
NITROUS-OXIDE
NNO
 
Nitral
Nitrious oxide
Nitrogen hypoxide
Nitrogen monoxide
Nitrogen oxide (N2O)
Nitrogen protoxide
Nitrogenium oxydulatum
Nitrous oxide
Nitrous oxide (JP15/USP)
Nitrous oxide (TN)
Nitrous oxide [Anaesthetics, volatile]
Nitrous oxide [JAN]
Nitrous oxide [UN1070] [Nonflammable gas]
Nitrous oxide [UN1070] [Nonflammable gas]
Nitrous oxide [anaesthetics, volatile]
Nitrous oxide [jan]
Nitrous oxide, JAN, USAN
Nitrous oxide, compressed
Nitrous oxide, refrigerated liquid
Nitrous oxide, refrigerated liquid [UN2201] [Nonflammable gas]
Nitrous oxide, refrigerated liquid [UN2201] [Nonflammable gas]
Nitrous-oxide
Oxide, Nitrous
Oxide, nitrous
Oxido nitroso
Oxido nitroso [Spanish]
Oxidodinitrogen(N--N)
Oxyde nitreux
Protoxyde d'azote [French]
Stickdioxyd
Stickdioxyd [German]
Stickstoff(I)-oxid
UN1070
UN2201
gaz hilarant
nitrogenium oxydulatum
nitrous oxide
oxidodinitrogen(N--N)
oxyde nitreux
protoxyde d'azote
19
IodinePhase 4, Phase 3, Phase 2, Phase 15167553-56-2807
Synonyms:
I2
Iode
Iodine-molecule
 
Iodio
Iodum
Jod
Jood
Tincture iodine
20
BenzocainePhase 4, Phase 3, Phase 1, Phase 2, Phase 017941994-09-7, 94-09-72337
Synonyms:
(p-(Ethoxycarbonyl)phenylamine
06952_FLUKA
112909_ALDRICH
112909_SIAL
1333-08-0
23239-88-5
23239-88-5 (hydrochloride)
4 Aminobenzoic Acid Ethyl Ester
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-14-00-01129 (Beilstein Handbook Reference)
4-Aminobenzoate
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Aminobenzoic acid, ethyl ester
4-Carbethoxyaniline
4-amino-benzoic acid ethyl ester
4-aminobenzoic acid ethyl ester
71123-91-6
94-09-7
94-09-7 (Parent)
A0271
AB00051923
AC1L1DGC
AC1Q341A
AC1Q64JE
AE-562/40377256
AI3-02081
AKOS000119763
AR-1H9065
Acetate, Benzocaine
Aethoform
Aethylium paraminobenzoicum
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthesinum
Anaesthin
Anestezin
Anestezin [Russian]
Anesthesin
Anesthesine
Anesthone
BB_SC-0019
BPBio1_001017
BRD-K75466013-001-05-2
BRN 0638434
BSPBio_000923
BSPBio_001908
Baby Anbesol
Bensokain
Benzoak
Benzocaina
Benzocaina [INN-Spanish]
Benzocaine
Benzocaine (USP/INN)
Benzocaine Acetate
Benzocaine Formate
Benzocaine Hydrobromide
Benzocaine Hydrochloride
Benzocaine Methanesulfonate
Benzocaine [INN:BAN]
Benzocainum
Benzocainum [INN-Latin]
Benzoic acid, 4-amino-, ethyl ester
Benzoic acid, 4-amino-, ethyl ester, hydrochloride
Benzoic acid, amino-, ethyl ester
Benzoic acid, p-amino-, ethyl ester
C07527
CAS-94-09-7
CHEBI:116735
CHEMBL278172
CID2337
Caswell No. 430A
Chloraseptic
D001566
D00552
DB01086
Dermoplast
Diet Ayds
DivK1c_000932
E1501_SIGMA
EINECS 202-303-5
EPA Pesticide Chemical Code 097001
ETHYL-P-AMINOBENZOATE
Ethoform
Ethoforme
Ethyl 4-aminobenzoate
Ethyl 4-aminobenzoate hydrochloride
Ethyl 4-aminobenzoic acid
Ethyl Aminobenzoate
Ethyl PABA
 
Ethyl aminobenzoate
Ethyl aminobenzoate (JP15)
Ethyl aminobenzoate (VAN)
Ethyl aminobenzoic acid
Ethyl p-Aminobenzoate
Ethyl p-Aminophenylcarboxylate
Ethyl p-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethylester kyseliny p-aminobenzoove
Ethylester kyseliny p-aminobenzoove [Czech]
Ethylis aminobenzoas
Formate, Benzocaine
HMS1570O05
HMS1920G09
HMS2091M11
HMS502O14
HSDB 7225
Hurricaine
Hydrobromide, Benzocaine
Hydrochloride, Benzocaine
I05-0204
IDI1_000932
Identhesin
KBio1_000932
KBio2_000474
KBio2_003042
KBio2_005610
KBio3_001408
KBioGR_000658
KBioSS_000474
Keloform
LS-35847
MLS001331704
MLS002153970
Methanesulfonate, Benzocaine
MolPort-000-871-526
NCGC00016352-01
NCGC00094598-01
NCGC00094598-02
NINDS_000932
NSC 122792
NSC 41531
NSC41531
NSC4688
Norcain
Norcaine
Norcainum
Oprea1_750694
Oprea1_827402
Ora-jel
Orabase-B
Orthesin
Otocain
Outgro
Parathesin
Parathesin (TN)
Parathesine
Prestwick0_000712
Prestwick1_000712
Prestwick2_000712
Prestwick3_000712
Prestwick_991
SMR000059025
SPBio_000134
SPBio_002844
SPECTRUM1500139
STK043620
Slim Mint Gum
Solarcaine
Solu H
Spectrum2_000117
Spectrum3_000314
Spectrum4_000249
Spectrum5_000860
Spectrum_000074
Topcaine
UNII-U3RSY48JW5
WLN: ZR DVO2
ZINC12358719
benzocaine
ethylaminobenzoate-4
h-4-abz-oet
nchembio.182-comp4
p-(Ethoxycarbonyl)aniline
p-Aminobenzoate
p-Aminobenzoic acid
p-Aminobenzoic acid ethyl ester
p-Aminobenzoic acid, ethyl ester
p-Aminobenzoic ethyl ester
p-Carbethoxyaniline
p-Ethoxycarboxylic Aniline
p-Ethoxycarboxylic aniline
21
MiconazolePhase 4, Phase 3, Phase 2, Phase 1, Phase 0357322916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
22lenograstimPhase 4, Phase 3, Phase 2, Phase 11178
23
FentanylPhase 4, Phase 3739437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
 
Fentanyl-12
Fentanyl-25
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
UNII-UF599785JZ
fentanyl
24
BupivacainePhase 4, Phase 3, Phase 210562180-92-9, 38396-39-32474
Synonyms:
( inverted exclamation markA)-bupivacaine
(+-)-Bupivacaine
(1)-1-Butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
(RS)-bupivacaine
(±)-bupivacaine
1-Butyl-2',6'-pipecoloxylidide
1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide
1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
15233-43-9
2180-92-9
38396-39-3
AB00053674
AC-2096
AC1L1DRE
AC1Q5LX4
AH 250
AKOS001637202
AR-1A0242
Anekain
BPBio1_000298
BRD-A01636364-003-05-2
BSPBio_000270
BSPBio_002607
Bio-0886
Bloqueina
Bucaine
Bucaine (TN)
Bupivacaina
Bupivacaina [INN-Spanish]
Bupivacaine (INN)
Bupivacaine Carbonate
Bupivacaine HCL
Bupivacaine HCL KIT
Bupivacaine Monohydrochloride, Monohydrate
Bupivacaine [INN:BAN]
Bupivacainum
Bupivacainum [INN-Latin]
Bupivan
C07529
C18H28N2O
CBupivacaine
CHEBI:3215
CHEMBL1098
CID2474
Carbostesin
D07552
DB00297
DL-Bupivacaine
DUR-843
 
DepoBupivacaine
DivK1c_000758
EINECS 218-553-3
EINECS 253-911-2
HMS2090F12
IDI1_000758
KBio1_000758
KBio2_002004
KBio2_004572
KBio2_007140
KBio3_001827
KBioGR_001516
KBioSS_002004
KST-1A4609
L000695
LAC-43
LS-109841
LS-2222
MLS001361336
Marcaina
Marcaine
Marcaine HCL
Marcaine Spinal
MolPort-004-955-820
NCGC00178579-01
NCGC00178579-02
NINDS_000758
NSC119660
Prestwick0_000305
Prestwick1_000305
Prestwick2_000305
Prestwick3_000305
SMR000058218
SPBio_001558
SPBio_002489
Sensorcaine
Sensorcaine-MPF
Sensorcaine-MPF Spinal
Spectrum2_001589
Spectrum3_000974
Spectrum4_001098
Spectrum5_001483
Spectrum_001524
Transdur-Bupivacaine
UNII-Y8335394RO
Win 11318
Win 11318 HCl
bupivacaine
cBupivacaine
dl-1-Butyl-2',6'-pipecoloxylidide
racemic bupivacaine
25
FulvestrantPhase 4, Phase 3, Phase 2, Phase 1182129453-61-8104741, 17756771
Synonyms:
(7R,13S,17S)-13-methyl-7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
(7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
(7R,8S,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl) nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
(7alpha,17beta)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-3,17-diol
129453-61-8
7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)estra-1,3,5(10)-triene-3,17-diol
7alpha-(9-((4,4,5,5,5,-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol
7alpha-(9-((4,4,5,5,5-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol
7alpha-[9[(4,4,5,5,5-Pentafluropentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene-3, 17 beta diol
AC-4693
AC1L2XEN
AstraZeneca brand of fulvestrant
BIDD:ER0348
BIDD:PXR0136
C070081
C32H47F5O3S
CCRIS 8741
CHEBI:404798
CHEMBL1358
CID104741
D01161
DB00947
Faslodex
Faslodex (TN)
 
Faslodex(ICI 182,780)
Faslodex, ICI 182780, Fulvestrant
Fulvestrant
Fulvestrant (JAN/USAN/INN)
Fulvestrant [USAN]
HMS2090N22
HSDB 7658
I06-1109
ICI 182,780
ICI 182,789
ICI-182780
Ici 182780
LS-64781
NCGC00164789-02
NSC719276
S1191_Selleck
UNII-22X328QOC4
ZD 182780
ZD-182780
ZD-9238
ZM 182780
ZM-182780
fulvestrant
nchembio.168-comp5
nchembio.76-comp5
nchembio775-comp4
26
DiazepamPhase 4, Phase 2, Phase 1114439-14-53016
Synonyms:
1-Methyl-5-phenyl-7-chloro-1,3-dihydro-2H-1,4-benzodiazepin-2-one
11100-37-1
439-14-5
5-24-04-00300 (Beilstein Handbook Reference)
53320-84-6
7-Chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one
7-Chloro-1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepine
7-Chloro-1-methyl-5-3H-1,4-benzodiazepin-2(1H)-one
7-Chloro-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one
7-Chloro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one
7-Chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2(1H)-one
7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one
7-chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one
A3662/0155188
AC-10561
AC1L1EZE
AKOS003367969
Alboral
Aliseum
Alupram
Amiprol
An-Ding
Ansilive
Ansiolin
Ansiolisina
Antenex
Anxicalm
Anxionil
Apaurin
Apo-Diazepam
Apo-diazepam
Apozepam
Armonil
Arzepam
Assival
Atensine
Atilen
Azedipamin
BIDD:GT0105
BIDD:PXR0158
BRD-K16508793-001-01-8
BRN 0754371
BSPBio_003279
Baogin
Bensedin
Benzopin
Best [Pharaceutical]
Betapam
Bialzepam
Britazepam
C06948
CB 4261
CCRIS 6009
CHEBI:49575
CHEMBL12
CID3016
CPD000058398
Calmaven
Calmocitene
Calmociteno
Calmod
Calmpose
Caudel
Centrazepam
Cercine
Ceregulart
Chuansuan
Condition
D-Pam
D00293
D003975
D0899_SIGMA
D9900_FLUKA
D9900_SIGMA
DAP
DB00829
DB07699
DEA No. 2765
DZP
Desconet
Desloneg
Diacepan
Diaceplex
Dialag
Dialar
Diapam
Diapax
Diapine
Diaquel
Diastat
Diastat (TN)
Diastat Acudial
Diatran
Diazapam
Diazem
Diazemuls
Diazemulus
Diazepam
Diazepam (JP15/USP/INN)
Diazepam Dak
Diazepam Desitin
Diazepam Elmu
Diazepam Fabra
Diazepam Intensol
Diazepam Nordic
Diazepam Rectubes
Diazepam Stada
Diazepam [USAN:INN:BAN:JAN]
Diazepam solution
Diazepam-Eurogenerics
Diazepam-Lipuro
Diazepam-ratiopharm
Diazepamu
Diazepamu [Polish]
Diazepamum
Diazepamum [INN-Latin]
Diazepan
Diazepan leo
Diazepin
Diazetard
Dienpax
Dipam
Dipaz
Dipezona
Disopam
DivK1c_000967
Dizac
Domalium
Doval
Drenian
Ducene
Duksen
Dupin
Duxen
E-Pam
EINECS 207-122-5
Elcion CR
Eridan
Euphorin P
Eurosan
Evacalm
Faustal
Faustan
Faustan,
Freudal
Frustan
Gewacalm
Gihitan
Gradual
Gubex
HMS2051N04
HMS503A15
HSDB 3057
I06-0194
IDI1_000967
Iazepam
 
Jinpanfan
KBio1_000967
KBio3_002780
KBioGR_001012
Kabivitrum
Kiatrium
Kratium
Kratium 2
LA 111
LA III
LA-111
LS-122
La-Iii
Lamra
Lembrol
Levium
Liberetas
Lizan
Lovium
MLS000759402
Mandro
Mandro-Zep
Mandrozep
Medipam
Mentalium
Metamidol
Methyl diazepinone
Methyldiazepinone
Methyldiazepinone (pharmaceutical)
Methyldiazepinone, pharmaceutical
Metil Gobanal
MolPort-001-729-114
Morosan
NCGC00178168-01
NINDS_000967
NSC 169897
NSC-77518
NSC169897
NSC77518
Nellium
Nerozen
Nervium
Neurolytril
Nivalen
Nixtensyn
Noan
Notense
Novazam
Novo-Dipam
Novodipam
Oprea1_126223
Ortopsique
Paceum
Pacitran
Paralium
Paranten
Parzam
Paxate
Paxel
Paxum
Placidox 10
Placidox 2
Placidox 5
Plidan
Pms-Diazepam
Pomin
Pro-Pam
ProPAM
Prozepam
Psychopax
Q-Pam
Q-Pam Relanium
Q-pam
Quetinil
Quiatril
Quievita
Radizepam
Relaminal
Relanium
Reliver
Renborin
Ro 5-2805
Ro 5-2807
Ruhsitus
S.A. R.L
S.a. r.l.
SAM001246536
SMR000058398
STK735517
Saromet
Sedapam
Sedipam
Seduksen
Seduxen
Serenack
Serenamin
Serenzin
Servizepam
Setonil
Sibazon
Sibazone
Sico Relax
Simasedan
Sipam
Solis
Sonacon
Spectrum3_001780
Spectrum4_000576
Spectrum5_001890
Stesolid
Stesolin
T-quil
Tensium
Tensopam
Tranimul
Trankinon
Tranqdyn
Tranquase
Tranquirit
Tranquo-Puren
Tranquo-Tablinen
Tranquo-puren
Tranquo-tablinen
Trazepam
UNII-Q3JTX2Q7TU
Umbrium
Unisedil
Usempax Ap
Usempax ap
Valaxona
Valeo
Valiquid
Valitran
Valium
Valium (TN)
Valium R
Valrelease
Valuzepam
Vanconin
Vatran
Vazen
Vazepam
Velium
Vival
Vivol
WLN: T67 GNV JN IHJ CG G1 KR
WY-3467
Winii
Wy 3467
ZINC00006427
Zepaxid
Zetran
Zipan
diazepam
e-Pam
nchembio.307-comp2
nchembio747-comp27
neurolytr il
27
NorepinephrinePhase 4, Phase 3, Phase 266451-41-2439260
Synonyms:
(-)-(R)-Norepinephrine
(-)-Arterenol
(-)-Arterenol free base
(-)-NORADRENALINE
(-)-Noradrenaline
(-)-Norepinephrine
(-)-alpha-(Aminomethyl)protocatechuyl alcohol
(R)-(-)-Norepinephrine
(R)-4-(2-Amino-1-hydroxyethyl)-1,2-benzenediol
(R)-4-(2-amino-1-Hydroxyethyl)-1,2-benzenediol
(R)-Noradrenaline
(R)-Norepinephrine
1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)- (9CI)
4-(2-Amino-1-hydroxyethyl)-1,2-benzenediol
4-[(1R)-2-Amino-1-hydroxyethyl]-1,2-benzenediol
4-[(1R)-2-amino-1-hydroxyethyl]benzene-1,2-diol
4899-05-2
51-40-1 (l-tartrate (1:1))
51-41-2
66197-73-7
A7257_SIGMA
AC1L96ZT
ALBB-006229
Adrenor
Aktamin
Arterenol
BRN 4231961
BSPBio_002079
C00547
CHEBI:18357
CHEMBL1437
CID439260
D-(-)-Noradrenaline
D00076
D53D5E3A-2360-4CA9-8031-6C2CD4062FD5
DB00368
DivK1c_000230
EINECS 200-096-6
HMS1920B08
HMS2089E18
HMS2091J08
HMS500L12
IDI1_000230
KBio1_000230
KBio2_001489
KBio2_004057
KBio2_006625
KBio3_001579
KBioGR_000635
KBioSS_001489
L-2-Amino-1-(3,4-dihydroxyphenyl)ethanol
L-3,4-Dihydroxyphenylethanolamine
L-3,4-dihydroxyphenylethanolamine
L-Arterenol
L-Noradrenaline
L-Norepinephrine
L-alpha-(Aminomethyl)-3,4-dihydroxybenzyl alcohol
L-alpha-(aminomethyl)-3,4-dihydroxybenzyl alcohol
L-arterenol
L-noradrenaline
LS-42676
LT03330026
 
LT4
Levarterenol
Levarterenolo
Levarterenolo [DCIT]
Levoarterenol
Levonor
Levonoradrenaline
Levonorepinephrine
Levophed
NCGC00159406-02
NCGC00159406-03
NCGC00159406-04
NCGC00159406-05
NCGC00159406-06
NCGC00159406-07
NCGC00159406-09
NINDS_000230
Nor adrenalin
Nor adrenalin (TN)
Nor-Epirenan
Nor-adrenaline
Noradrenalin
Noradrenalina
Noradrenalina [Italian]
Noradrenaline
Noradrenaline (JP15)
Noradrenalinum
Norartrinal
Noreinefrina
Noreinefrina [INN-Spanish]
Norepinefrina
Norepinephrine
Norepinephrine (INN)
Norepinephrine Noradrenalin
Norepinephrine [INN:JAN]
Norepinephrine l-Tartrate (1:1)
Norepinephrinum
Norepinephrinum [INN-Latin]
Norepirenamine
PDSP1_001111
PDSP2_001095
SGCUT00123
SPBio_001048
SPECTRUM1500436
STK503776
Spectrum2_001064
Spectrum3_000520
Spectrum4_000078
Spectrum5_001068
Spectrum_001009
Sympathin E
UNII-X4W3ENH1CV
bmse000404
l-1-(3,4-Dihydroxyphenyl)-2-aminoethanol
l-2-Amino-1-(3,4-dihydroxyphenyl)ethanol
nchembio.284-comp2
nchembio.64-comp2
nchembio705-1
noradrenaline
norepinefrina
norepinephrine
norepinephrinum
to_000024
28
s 1 (combination)Phase 4, Phase 2343
Synonyms:
 
Gimeracil / oteracil / tegafur
TS 1
29
Povidone-iodinePhase 4, Phase 314425655-41-8
Synonyms:
 
Betadine
30
EthanolPhase 4, Phase 2, Phase 3, Phase 1197164-17-5702
Synonyms:
(C6-C9)Alkyl alcohol
02483_FLUKA
02851_FLUKA
02853_FLUKA
02854_FLUKA
02855_FLUKA
02856_FLUKA
02856_SIAL
02857_FLUKA
02857_SIAL
02858_FLUKA
02858_SIAL
02860_FLUKA
02865_FLUKA
02865_SIAL
02870_FLUKA
02870_SIAL
02875_FLUKA
02877_FLUKA
02878_FLUKA
02882_FLUKA
02882_SIAL
02883_FLUKA
02884_FLUKA
02890_FLUKA
02890_SIAL
02891_FLUKA
02891_SIAL
1-Hydroxyethane
100C.NPA
121182-78-3
187380_ALDRICH
187380_SIAL
24102_RIEDEL
24102_SIAL
24103_RIEDEL
24103_SIAL
24105_RIEDEL
24105_SIAL
24106_RIEDEL
24106_SIAL
24194_RIEDEL
24194_SIAL
245119_ALDRICH
245119_SIAL
270741_ALDRICH
270741_SIAL
277649_ALDRICH
277649_SIAL
2858_SIGMA
29221_FLUKA
32205_RIEDEL
32205_SIAL
32221_RIEDEL
32221_SIAL
32294_RIEDEL
32294_SIAL
34870_SIAL
34963_RIEDEL
39278_FLUKA
40210_ALDRICH
40210_RIEDEL
41322_FLUKA
458600_ALDRICH
458600_SIAL
459828_ALDRICH
459828_SIAL
459836_ALDRICH
459836_SIAL
459844_SIAL
48075_SUPELCO
493511_SIAL
493538_ALDRICH
493538_SIAL
493546_ALDRICH
493546_SIAL
64-17-5
676829_SIAL
68475-56-9
71076-86-3
71329-38-9
8000-16-6
8024-45-1
AC1L19TW
AC1Q31MM
AHD 2000
AI3-01706
ALCOHOL 5% IN D5-W
Absolute Alcohol
Absolute Ethanol
Absolute alcohol
Absolute ethanol
Absolute ethyl alcohol
Aethanol
Aethanol [German]
Aethylalkohol
Alcare Hand Degermer
Alcohol
Alcohol (USP)
Alcohol (ethyl)
Alcohol Anhydrous
Alcohol [USP]
Alcohol anhydrous
Alcohol dehydrated
Alcohol denatured
Alcohol etílico
Alcohol, Absolute
Alcohol, Dehydrated
Alcohol, Diluted
Alcohol, Grain
Alcohol, anhydrous
Alcohol, dehydrated
Alcohol, denatured
Alcohol, diluted
Alcohol, ethyl
Alcohols
Alcohols, C1-3
Alcohols, C30
Alcohols, C6-9
Alcool Ethylique
Alcool Etilico
Alcool ethylique
Alcool etilico
Alcool éthylique
Algrain
Alkohol
Alkohol [German]
Alkoholu Etylowego
Alkoholu etylowego
Aminoethanol
Anhydrol
Anhydrol PM 4085
Anhydrous alcohol
Anhydrous ethanol
Beta-Aminoethanol
Beta-Aminoethyl Alcohol
Beta-Ethanolamine
Beta-Hydroxyethylamine
C00469
C2H5OH
C2H6O
CCRIS 945
CDA 19
CDA 19-200
CHEBI:16236
CHEMBL545
CID702
Caswell No. 426
Caswell No. 430
Colamine
Cologne Spirit
Cologne spirit
Cologne spirits
 
D000431
D00068
DB00898
Dehydrated Ethanol
Dehydrated alcohol
Dehydrated ethanol
Denatured Alcohol
Denatured Alcohol Cd-10
Denatured Alcohol Cd-5
Denatured Alcohol Cd-5a
Denatured Alcohol Sd-1
Denatured Alcohol Sd-13a
Denatured Alcohol Sd-17
Denatured Alcohol Sd-23a
Denatured Alcohol Sd-28
Denatured Alcohol Sd-30
Denatured Alcohol Sd-39b
Denatured Alcohol Sd-39c
Denatured Alcohol Sd-3a
Denatured Alcohol Sd-40m
Denatured Ethanol
Denatured alcohol
Denatured ethanol
Desinfektol EL
Diluted Alcohol
Distilled spirits
E2385_SIGMA
E7023_ALDRICH
E7023_SIAL
E7148_ALDRICH
E7148_SIAL
E7517_SIGMA
EINECS 200-578-6
EINECS 270-649-4
EOH
EOX
ETA
Envision Conditioner Pdd 9020
Esumiru WK 88
EtOH
Etanolo
Etanolo [Italian]
Ethanol (9CI)
Ethanol 200 Proof
Ethanol 200 proof
Ethanol Absolute
Ethanol Absolute Bp
Ethanol Anhydrous
Ethanol Extra Pure
Ethanol Vapor
Ethanol [JAN]
Ethanol solution
Ethanol, Silent Spirit
Ethanol, undenatured
Ethanolum anhydricum
Ethicap
Ethyl Alcohol
Ethyl Alcohol & Water, 10%
Ethyl Alcohol & Water, 20%
Ethyl Alcohol & Water, 30%
Ethyl Alcohol & Water, 40%
Ethyl Alcohol & Water, 5%
Ethyl Alcohol & Water, 50%
Ethyl Alcohol & Water, 60%
Ethyl Alcohol & Water, 70%
Ethyl Alcohol & Water, 80%
Ethyl Alcohol & Water, 95%
Ethyl Alcohol & Water, 96%
Ethyl Alcohol Anhydrous
Ethyl Alcohol, Anhydrous
Ethyl Alcohol, Denatured
Ethyl Hydrate
Ethyl Hydroxide
Ethyl alc
Ethyl alcohol
Ethyl alcohol anhydrous
Ethyl alcohol in alcoholic beverages
Ethyl alcohol usp
Ethyl hydrate
Ethyl hydroxide
Ethylalcohol
Ethylalcohol [Dutch]
Ethylol
Ethylolamine
Ethyloxy Group
Etylowy alkohol
FEMA No. 2419
FEMA Number 2419
Fermentation alcohol
Glycinol
Grain alcohol
HSDB 531
HSDB 82
HYDROXYETHYL GROUP
Hinetoless
Hydroxyethane
I14-12648
IMS 99
Infinity Pure
Jaysol
Jaysol S
LS-1539
LTBB002977
Lux
Methylated Spirit Mineralised
Methylated spirit
Methylcarbinol
MolPort-001-785-844
Molasses alcohol
NCGC00091458-01
NCI-C03134
NSC 85228
NSC85228
Oxydimethylene Group
Potato alcohol
Punctilious ethyl alcohol
Pyro
QMHAIh@
Reagent Alcohol
Ru-Tuss Expectorant
SDA 3A
SDA 40-2
SDM No. 37
SY Fresh M
Sekundasprit
Silent spirit
Spirit
Spirits of wine
Spiritus vini
Spirt
Synasol
Tecsol
Tecsol C
Thanol
Thiofaco M-50
UNII-3K9958V90M
USAF EK-1597
Undenatured Ethanol
WLN: Q2
absolute alcohol
alcohol
alcohol etilico
bmse000297
etanol
ethanol
ethyl alcohol
grain alcohol
nchem.651-comp3c
nchembio.552-comp10
nchembio.94-comp20
spiritus vini
Äthanol
Äthylalkohol
éthanol
31
PamidronatePhase 4, Phase 3, Phase 24440391-99-94674
Synonyms:
(3-AMINO-1-HYDROXY-1-PHOSPHONO-PROPYL)PHOSPHONIC ACID
(3-Amino-1-hydroxypropylidene)bisphosphonic acid
(3-Amino-1-hydroxypropylidene)diphosphonic acid
(3-amino-1-hydroxy-1-phosphonopropyl)phosphonic acid
(3-amino-1-hydroxypropane-1,1-diyl)bis(phosphonic acid)
(3-amino-1-hydroxypropylidene)-1,1-biphosphonate
(3-amino-1-hydroxypropylidene)-1,1-bisphosphonate
1-hydroxy-3-aminopropane-1,1-diphosphonic acid
3-Amino-1-hydroxypropylidene-1,1-diphosphonate
40391-99-9
57248-88-1
57248-88-1 (di-hydrochloride salt)
AC1L1IP4
AHPrBP
AKOS003599275
APD
Acide pamidronique
Acide pamidronique [INN-French]
Acido pamidronico
Acido pamidronico [INN-Spanish]
Acidum pamidronicum
Acidum pamidronicum [INN-Latin]
Amidronate
Aminomux
Aredia
BIDD:GT0538
Bisphosphonate 6
C019248
C07395
C3H11NO7P2
 
CHEMBL834
CID4674
ChemDiv1_025240
D07281
DB00282
EINECS 254-905-2
HMS2090C13
HMS658L06
HSCI1_000312
I14-2407
LS-174826
MolPort-002-131-054
NCGC00159433-02
NCGC00159433-03
Novartis brand of pamidronate disodium salt
PAMIDRONATE DISODIUM
PAMIDRONIC ACID
Pamidronate Disodium
Pamidronic acid
Pamidronic acid (INN)
Pamidronic acid [INN:BAN]
Ribodroat
Ribodroat (TN)
STOCK1N-12562
UNII-OYY3447OMC
amino-1-hydroxypropane-1,1-diphosphonate
aminohydroxypropylidene diphosphonate
aminopropanehydroxydiphosphonate
pamidronate
pamidronate calcium
pamidronate monosodium
32
EverolimusPhase 4, Phase 3, Phase 2, Phase 1, Phase 01863159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
everolimus
33
sirolimusPhase 4, Phase 3, Phase 2, Phase 1, Phase 0186353123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
34
CarboplatinPhase 4, Phase 3, Phase 2, Phase 1, Phase 0194241575-94-410339178, 498142, 38904
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
35Chlorhexidine gluconatePhase 4448
36
ChlorhexidinePhase 444855-56-19552079, 2713
Synonyms:
1,1 inverted exclamation marka-Hexamethylenebis[5-(4-chlorophenyl)biguanide]
1,1'-Hexamethylene bis(5-(P-chlorophenyl)biguanide)
1,1'-Hexamethylene bis(5-(p-chlorophenyl)biguanide)
1,1'-Hexamethylenebis(5-(p-chlorophenyl)biguanide)
1,1'-Hexamethylenebis[5-(4-chlorophenyl)biguanide
1,6-Bis(5-(p-chlorophenyl)biguandino)hexane
1,6-Bis(p-chlorophenyldiguanido)hexane
1,6-Di(4'-chlorophenyldiguanido)hexane
1,6-Di(N-p-chlorophenyldiguanido)hexane
24798_FLUKA
282227_ALDRICH
348031_ALDRICH
4-12-00-01201 (Beilstein Handbook Reference)
55-56-1
AB00053427
AB1003159
AVAGARD
BPBio1_000272
BRN 2826432
BSPBio_000246
BSPBio_001977
C06902
C22H30Cl2N10
CAS-55-56-1
CCRIS 9230
CHEBI:3614
CHEMBL790
CID9552079
Chlorhexidin
Chlorhexidin [Czech]
Chlorhexidine
Chlorhexidine (INN)
Chlorhexidine Base
Chlorhexidine [INN:BAN]
Chlorhexidine gluconate
Chlorhexidinum
Chlorhexidinum [INN-Latin]
Cloresidina
Cloresidina [DCIT]
Clorhexidina
Clorhexidina [INN-Spanish]
D07668
DB00878
Decanoylacetaldehyde Sodium Sulfide
Dentisept [veterinary]
Dentisept [veterinary] (TN)
DivK1c_000761
EINECS 200-238-7
Fimeil
HMS1568M08
HSDB 7196
Hexadol
Hibiclens
Hibispray
Hibistat
I06-0621
I14-0050
IDI1_000761
 
KBio1_000761
KBio2_000717
KBio2_003285
KBio2_005853
KBio3_001197
KBioGR_000774
KBioSS_000717
LS-43917
Lisium (*Dihydrochloride*)
MK-412A
MLS001332387
MLS001332388
MLS002154209
Merfen-incolore
Merfen-incolore (TN)
MolPort-002-541-741
N',N'''''-hexane-1,6-diylbis[N-(4-chlorophenyl)(imidodicarbonimidic diamide)]
N,N''''-hexane-1,6-diylbis[N'-(4-chlorophenyl)(imidodicarbonimidic diamide)]
N,N'-Bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradeca- nediimidamide
N,N'-Bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide
N,N'-bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide
NCGC00016246-01
NCGC00091025-01
NCGC00091025-02
NINDS_000761
NSC526936
Nolvasan
Nolvasan (*Diacetate*)
Novalsan
Oro-Clense
Peridex
Periogard
Prestwick0_000143
Prestwick1_000143
Prestwick2_000143
Prestwick3_000143
Prestwick_53
QTL1_000020
Rotersept
SMR000857146
SPBio_000210
SPBio_002185
STK089248
STOCK1S-18831
Savloclens
Savlon babycare
Sebidin A
Sodium Houttuyfonamide
Soretol
Spectrum2_000135
Spectrum3_000339
Spectrum4_000277
Spectrum5_001322
Spectrum_000237
Sterido
Sterilon
Superspray
Tubulicid
UNII-R4KO0DY52L
chlorhexidine
37
ToremifenePhase 4, Phase 3, Phase 22689778-26-73005573
Synonyms:
(Z)-2-(4-(4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine
2-(p-[(Z)-4-chloro-1,2-diphenyl-1-butenyl]-phenoxy)-N,N-dimethyl-ethylamine citrate(1:1)
2-(para-((Z)-4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylethylamine (IUPAC)
2-({4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenyl}oxy)-N,N-dimethylethanamine
2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine
2-{4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine
89778-26-7
89778-27-8 (citrate (1:1))
98644-21-4
AC-1751
AC1MHJ33
Acapodene
BIDD:ER0222
BIDD:GT0211
BIDD:PXR0202
C08166
CCRIS 8745
CHEBI:9635
CHEMBL1655
CID3005573
D08620
DB00539
 
Estrimex
FC-1157a
Farestone
GTX-006 (Acapodene)
GTx 006
GTx-006
HMS2090B22
LS-7729
MolPort-002-508-208
NCGC00160530-01
STK626445
STOCK6S-27411
Toremifene (INN)
Toremifene Base
Toremifene Citrate (1:1)
Toremifene [INN:BAN]
Toremifeno
Toremifeno [Spanish]
Toremifenum
Toremifenum [Latin]
UNII-7NFE54O27T
Z-Toremifene
toremifene
{2-[4-(4-Chloro-1,2-diphenyl-but-1-enyl)-phenoxy]-ethyl}-dimethyl-amine
38
PropofolPhase 4, Phase 3, Phase 29852078-54-84943
Synonyms:
2, 6-Diisopropylphenol
2,6 Diisopropylphenol
2,6-Bis(1-methylethyl)phenol
2,6-Bis(Isopropyl)-phenol
2,6-DIISOPROPYLPHENOL
2,6-Diisopropyl phenol
2,6-Diisopropylphenol
2,6-bis(1-methylethyl)-phenol
2,6-di(propan-2-yl)phenol
2078-54-8
28449-97-0
4-06-00-03435 (Beilstein Handbook Reference)
50356-15-5
AB00513968
AC-2038
AC1L1J9Y
AC1Q1OUI
AI3-26295
AM-149
Abbott Brand of Propofol
Alpha Brand of Propofol
Ampofol
Aquafol
Astra Brand of Propofol
AstraZeneca Brand of Propofol
BIDD:GT0436
BPBio1_000950
BPBio1_000969
BRD-K82255054-001-03-5
BRN 1866484
BSPBio_000862
Biomol-NT_000248
Braun Brand of Propofol
C07523
C12H18O
CAS-2078-54-8
CCRIS 9000
CHEBI:44915
CHEMBL526
CID4943
CPD-11437
CPD000059151
Curamed Brand of Propofol
D00549
D015742
D0617
D126608
D126608_ALDRICH
DB00818
DDS-04F
Diisopropylphenol
Dipravan
Diprivan
Diprivan (TN)
Diprivan Injectable emulsion
Disoprivan
Disoprofol
EINECS 218-206-6
EU-0100437
Fresenius Brand of Propofol
Fresenius Kabi Brand of Propofol
Fresofol
HMS1570L04
HMS2089O21
HMS2094E17
 
HSDB 7123
ICI 35,868
ICI 35868
ICI-35,868
ICI-35868
ICI35,868
ICI35868
InChI=1/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H
Ivofol
Jsp004266
Juste Brand of Propofol
LS-996
Lopac-D126608
Lopac0_000437
MLS001066348
MLS001335999
MLS002454360
MolPort-001-794-517
NCGC00015389-01
NCGC00015389-02
NCGC00015389-04
NCGC00015389-09
NCGC00091538-01
NCGC00091538-02
NCGC00091538-03
NCGC00091538-04
NCGC00091538-05
NCGC00091538-06
NSC 5105
NSC5105
PFL
Parnell Brand of Propofol
Pisa Brand of Propofol
Prestwick0_000931
Prestwick1_000931
Prestwick2_000931
Prestwick3_000931
Propofol
Propofol (JAN/USAN/INN)
Propofol Abbott
Propofol Fresenius
Propofol IDD-D
Propofol MCT
Propofol Rovi
Propofol [USAN:INN:BAN]
Propofol(2,6-Diisopropylphenol)
Propofol-Lipuro
Propofolum
Propofolum [Latin]
Rapinovet
Recofol
Rovi Brand of Propofol
S01-0189
SAM002264610
SMR000059151
SPBio_003031
SPECTRUM1505022
ST50405911
Schering Brand of Propofol
UNII-YI7VU623SF
W505102_ALDRICH
ZD-0859
ZINC00968303
Zeneca Brand of Propofol
ghl.PD_Mitscher_leg0.558
nchembio.552-comp7
propofol
39
substance PPhase 4, Phase 323933507-63-044359816
Synonyms:
 
Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2
40
SerotoninPhase 4, Phase 3, Phase 2, Phase 1351050-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine
41
OndansetronPhase 4, Phase 3, Phase 229699614-02-54595
Synonyms:
(RS)-1,2,3,9-Tetrahydro-9-methyl-3-(2-methylimidazol-1-ylmethyl)carbazol-4-one
1,2,3,9-Tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-4H-carbazol-4-one
103639-04-9 (mono-hydrochloride dihydrate)
108303-49-7
116002-70-1
9-Methyl-3-(2-methyl-imidazol-1-ylmethyl)-1,2,3,9-tetrahydro-carbazol-4-one
9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,9-tetrahydro-4H-carbazol-4-one
9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one
99614-01-4 (mono-hydrochloride)
99614-02-5
AB00373674
AC1L1IIM
AKOS000599484
Apo-ondansetron
BAS 00717177
BPBio1_001118
BRD-A19736161-001-01-8
BRD-A19736161-003-03-0
BRN 3622981
BSPBio_001016
C07325
C18H19N3O
CBDivE_008994
CHEMBL46
CID4595
CPD001307702
D00456
DB00904
DESMETHYLONDANSETRON
GR 38032
GR 38032X
GR-38032F
GR38032F
HMS2090H16
I06-0687
I06-1329
 
L000456
LS-172305
LS-51878
MolPort-001-944-253
NCI60_022780
Novo-ondansetron
Ondansetron
Ondansetron (JAN/USP/INN)
Ondansetron [USAN:INN:BAN]
Ondansetron, (+,-)-Isomer
Oprea1_435466
Oprea1_852372
PHL-ondansetron
PMS-ondansetron
Prestwick0_001058
Prestwick1_001058
Prestwick2_001058
Prestwick3_001058
Ratio-ondansetron
SAM002589958
SN-307
SPBio_002938
STK370548
STOCK4S-10990
Sandoz ondansetron
TL8006071
TimTec1_001750
UNII-4AF302ESOS
ZOFRAN IN PLASTIC CONTAINER
Zofran
Zofran ODT
Zofran ODT (TN)
Zofran odt
Zophren
Zudan
ondansetron
ondansetron (Zofran)
42
LidocainePhase 4, Phase 3, Phase 21168137-58-63676
Synonyms:
.alpha.-(Diethylamino)-2,6-acetoxylidide
.alpha.-Diethylamino-2,6-dimethylacetanilide
.alpha.-Diethylaminoaceto-2,6-xylidide
.omega.-Diethylamino-2,6-dimethylacetanilide
137-58-6
2-(Diethylamino)-2',6'-acetoxylidide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide
2-Diethylamino-N-(2,6-dimethylphenyl)acetamide
4-12-00-02538 (Beilstein Handbook Reference)
6108-05-0 (MONOHYDROCHLORIDE MONOHYDRATE))
6108-05-0 (mono-hydrochloride, mono-hydrate)
73-78-9 (mono-hydrochloride)
AB00053581
AC-10282
AC1L1GGQ
AC1Q2Z7J
AKOS001026768
ARONIS23855
After Burn Double Strength Gel
After Burn Double Strength Spray
After Burn Gel
After Burn Spray
Alphacaine
Anestacon
Anestacon Jelly
BIDD:GT0342
BPBio1_000197
BRD-K52662033-001-02-6
BRD-K52662033-003-05-5
BRN 2215784
BSPBio_000179
BSPBio_001359
BSPBio_003004
Bio-0767
Bio1_000379
Bio1_000868
Bio1_001357
Bio2_000079
Bio2_000559
C07073
C14H22N2O
CAS-73-78-9
CDS1_000283
CHEBI:6456
CHEMBL79
CID3676
CPD000058189
Cappicaine
Cito optadren
Cuivasil
D00358
DB00281
Dalcaine
Dentipatch
Dentipatch (TN)
DermaFlex
Diethylaminoaceto-2,6-xylidide
Dilocaine
DivK1c_000174
DivK1c_001323
Duncaine
EINECS 205-302-8
ELA-Max
EMBOLEX
Emla
Emla Cream
Esracaine
FT-0082378
Gravocain
HMS1791D21
HMS1989D21
HMS2051C21
HMS2089E15
HMS548M19
HSDB 3350
I01-2704
IDI1_000174
IDI1_033829
Isicaina
Isicaine
Jetocaine
KBio1_000174
KBio2_000079
KBio2_001598
KBio2_002647
KBio2_004166
KBio2_005215
KBio2_006734
KBio3_000157
KBio3_000158
KBio3_002224
KBioGR_000079
KBioGR_000599
KBioSS_000079
KBioSS_001598
L-Caine
L0156
L1026_SIGMA
L7757_SIGMA
LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE)
LIDOPEN
LQZ
 
LS-805
Lanabiotic
Leostesin
Lida-Mantle
Lidocaina
Lidocaina [INN-Spanish]
Lidocaine (JP15/USP/INN)
Lidocaine (VAN)
Lidocaine Carbonate
Lidocaine Hydrocarbonate
Lidocaine Monohydrochloride
Lidocaine [USAN:INN:JAN]
Lidocainum
Lidocainum [INN-Latin]
Lidocaton
Lidoderm
Lidoject-1
Lidoject-2
Lignocaine
Lignocainum
Lingocaine
Lopac-L-5647
Lopac0_000669
MLS000069724
MLS000758263
MLS001074177
Maricaine
Maybridge1_002571
MolPort-001-783-478
N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide
N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide
NCGC00015611-01
NCGC00015611-02
NCGC00015611-03
NCGC00015611-04
NCGC00015611-14
NCGC00022176-05
NCGC00022176-06
NCGC00022176-07
NCGC00022176-08
NCGC00022176-09
NINDS_000174
NSC 40030
NSC40030
Norwood Sunburn Spray
Octocaine
Octocaine-100
Octocaine-50
Prestwick0_000050
Prestwick1_000050
Prestwick2_000050
Prestwick3_000050
Remicaine
Rocephin Kit
Rucaina
S1357_Selleck
SAM001247018
SMR000058189
SPBio_001525
SPBio_002100
STK552033
Solarcaine
Solarcaine aloe extra burn relief cream
Solcain
Spectrum2_001343
Spectrum3_001392
Spectrum4_000070
Spectrum5_001549
Spectrum_001118
UNII-98PI200987
WLN: 2N2 & 1VMR B1 F1
Xilina
Xilocaina
Xilocaina [Italian]
Xllina
Xycaine
Xylestesin
Xylesthesin
Xylocain
Xylocaine
Xylocaine (TN)
Xylocaine 5% Spinal
Xylocaine CO2
Xylocaine Dental Ointment
Xylocaine Endotracheal
Xylocaine Test Dose
Xylocaine Viscous
Xylocaine-MPF
Xylocaine-MPF with Glucose
Xylocaine-Mpf
Xylocaine-Mpf with Glucose
Xylocard
Xylocitin
Xyloneural (free base)
Xylotox
Zilactin-L
Zingo
alfa-Dietilamino-2,6-dimetilacetanilide
alfa-Dietilamino-2,6-dimetilacetanilide [Italian]
alpha-Diethylamino-2,6-dimethylacetanilide
alpha-diethylamino-2,6-dimethylacetanilide
lidocaine
nchembio.65-comp16
α-diethylamino-2,6-dimethylacetanilide
43calcium channel blockersPhase 4, Phase 3, Phase 2, Phase 11889
44
zoledronatePhase 4, Phase 3, Phase 2, Phase 1290118072-93-868740
Synonyms:
(1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid
(1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid
(1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid
(1-hydroxy-2-imidazol-1-yl-phosphonoethyl)phosphonic acid monohydrate
(1-hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid
118072-93-8
2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid
2-(imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid
AC-1092
AC1L2ACJ
AC1Q6RN3
AKOS005145739
Aclasta
Anhydrous Zoledronic Acid
BIDD:GT0292
BIDD:PXR0134
Bio-0112
Bisphosphonate 3
C088658
CGP 42'446
CGP 42446
CGP 42446A
CGP-42'446
CGP-42446
CHEBI:46557
CHEMBL924
CID68740
D08689
DB00399
 
FT-0082657
HMS2089O09
I06-0710
KS-1132
LS-181815
MolPort-002-885-874
MolPort-003-850-890
NCGC00159521-02
NCGC00159521-03
NSC721517
Novartis brand of zoledronic acid
Reclast
Reclast (TN)
S00092
S1314_Selleck
UNII-70HZ18PH24
ZOL
Zol
Zoledronate
Zoledronic Acid Anhydrous
Zoledronic Acid, Anhydrous
Zoledronic acid
Zoledronic acid (INN)
Zoledronic acid [USAN:INN]
Zometa
Zometa (Novartis)
Zometa (TN)
Zometa Concentrate
Zometa, Zomera, Aclasta and Reclast, Zoledronic Acid
[1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid)
45Risedronate SodiumPhase 4, Phase 398115436-72-1
46neurokinin APhase 4, Phase 3242
47
FosaprepitantPhase 4, Phase 3157172673-20-0219090
Synonyms:
Fosaprepitantum
 
L-758,298
L-758298
48
BevacizumabPhase 4, Phase 3, Phase 2, Phase 1, Phase 01938216974-75-3
Synonyms:
216974-75-3
Avastin
Avastin (TN)
Bevacizumab
Bevacizumab (genetical recombination)
 
Bevacizumab (genetical recombination) (JAN)
D06409
R-435
anti-VEGF monoclonal antibody
antiVEGF
bevacizumab
49taxanePhase 4, Phase 3, Phase 2, Phase 1, Phase 0335
50
AnastrozolePhase 4, Phase 3, Phase 2, Phase 1, Phase 0266120511-73-12187
Synonyms:
.alpha.,alpha.,.alpha.',.alpha.'-tetramethyl-5(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
1,3-benzenediacetonitrile, a, a, a', a'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)
120511-73-1
2,2'-(5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile)
2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropanenitrile)
2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)benzene-1,3-diyl]bis(2-methylpropanenitrile)
2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile
AC-4234
AC1L1D49
Anastrazole
Anastrole
Anastrozol
Anastrozole (JAN/USAN/INN)
Anastrozole [USAN:INN:BAN]
Arimidex
Arimidex (TN)
Arimidex (Zeneca)
Arimidex, Anastrozole
Asiolex
Astra brand of anastrozole
AstraZeneca brand of anastrozole
C08159
C090450
C17H19N5
CHEBI:2704
CHEMBL1399
CID2187
CPD000466301
 
D00960
DB01217
HMS2052M11
HMS2089N10
HSDB 7462
I06-0021
ICI D1033
ICI-D 1033
ICI-D1033
LS-29563
MLS000759396
MLS001424217
MolPort-005-933-078
NCGC00164619-01
NSC719344
S1188_Selleck
SAM001246525
SBB066057
SMR000466301
UNII-2Z07MYW1AZ
ZD 1033
ZD-1033
ZD1033
ZINC00000941
Zeneca ZD 1033
Zeneca brand of anastrozole
alpha,alpha,Alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
alpha,alpha,alpha',alpha'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
anastrazole
anastrozole

Interventional clinical trials:

(show top 50)    (show all 5081)
idNameStatusNCT IDPhase
1EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast CancerApproved for marketingNCT00338247Phase 4
2Effects of Tamoxifen in Premenopausal Women With Benign Breast Disease Not at High-Risk of Developing Breast CancerCompletedNCT00999921Phase 4
3Wellbutrin XL, Major Depressive Disorder and Breast CancerCompletedNCT00234195Phase 4
4Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer PatientsCompletedNCT01129336Phase 4
5Study Comparing Full-dose Radiotherapy Versus Reduced Dose in the Management of Bone Metastasis in Patients With Breast Cancer Receiving Zoledronic AcidCompletedNCT00172029Phase 4
6Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast CancerCompletedNCT01961544Phase 4
7Arthralgia During Anastrozole Therapy for Breast CancerCompletedNCT00323479Phase 4
8An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)CompletedNCT00726661Phase 4
9A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast CancerCompletedNCT00121836Phase 4
10A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Patients With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin TreatmentCompletedNCT01301729Phase 4
11Prospective Validation Trial of Circulating Tumor Cells (CTCs) in Women With Metastatic Breast CancerCompletedNCT00493350Phase 4
12Liver Safety Under Upfront Arimidex vs TamoxifenCompletedNCT00537771Phase 4
13A Study of Avastin With Taxane Therapy in Patients With Triple Negative Breast CancerCompletedNCT01094184Phase 4
14Maintenance Treatment With Liposomal Doxorubicin (Caelyx) in Metastatic Breast Cancer PatientsCompletedNCT00128778Phase 4
15XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast CancerCompletedNCT00127933Phase 4
16Life Quality and Mental State in Patients With Breast CancerCompletedNCT01458457Phase 4
17Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast CancerCompletedNCT00742222Phase 4
18Accelerated Radiotherapy Outcomes in WomenCompletedNCT00156130Phase 4
19An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)CompletedNCT00092183Phase 4
20Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast CancerCompletedNCT00334139Phase 4
21Protexa® Versus TiLoopBra® in Immediate Breast Reconstruction- A Pilot StudyCompletedNCT02562170Phase 4
22Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone LesionsCompletedNCT00029224Phase 4
23Symptom Management After Breast Cancer SurgeryCompletedNCT00686127Phase 4
24Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor TherapyCompletedNCT00485953Phase 4
25Epoetin Alfa in Treating Chemotherapy-Related Anemia in Women With Stage I, Stage II, or Stage III Breast CancerCompletedNCT00022386Phase 4
26Reducing Pain and Disability After Breast Cancer SurgeryCompletedNCT01089933Phase 4
27Prevention of Post-Mastectomy Breast Pain Using Ambulatory Continuous Paravertebral BlocksCompletedNCT01231204Phase 4
28A Prospective,Open-label Study of Anastrozole in Post-menopausal Women With Hormone Sensitive Advanced Breast CancerCompletedNCT00544986Phase 4
29Chlorhydrate of Ropivacaine and Breast Cancer SurgeryCompletedNCT00370240Phase 4
30Study of Autologous Fat Enhanced w/ Regenerative Cells Transplanted to Reconstruct Breast Deformities After LumpectomyCompletedNCT00616135Phase 4
31Home-based Compression Therapy for Arm and Truncal Lymphedema in Breast CancerCompletedNCT00880022Phase 4
32Will Preoperative MRI Breast in Women Under 56 Years With Breast Cancer Change Primary TreatmentCompletedNCT01859936Phase 4
33PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy to Prevent NeutropeniaCompletedNCT02805205Phase 4
34Use of the Contura™ Catheter to Deliver Accelerated Partial Breast Irradiation to "Low-risk" Breast Cancer PatientsCompletedNCT00882596Phase 4
35Case-Control-Study on the Breast Cancer Risk of Mirena® Compared With Copper IUDsCompletedNCT00461253Phase 4
36Randomized Trial of Follow-up Strategies in Breast CancerCompletedNCT00156039Phase 4
37Low Level Laser Treatment and Breast Cancer Related LymphedemaCompletedNCT00852930Phase 4
38Incidence of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With the Docetaxel-Cyclophosphamide Regimen in Early Breast Cancer PatientsCompletedNCT01298193Phase 4
39Research Of Quality Of Life And Safety Outcomes Of Postmenopausal Breast Cancer Patients Switching From Tamoxifen Therapy To Aromatase Inhibitor TherapyCompletedNCT00784888Phase 4
40Breast VCEUS to Evaluate Early Response to Neoadjuvant ChemotherapyCompletedNCT01817374Phase 4
41Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml®CompletedNCT01448447Phase 4
42Pamidronate Administration in Breast Cancer Patients With Bone MetastasesCompletedNCT00128297Phase 4
43Comparative Efficiency of Three Regimen, CEFci, CEF and EC as Neoadjuvant Chemotherapy for Primary Breast CancerCompletedNCT01199432Phase 4
44Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast CancerCompletedNCT00375752Phase 4
45Letrozole in Treating Postmenopausal Women With Metastatic Breast CancerCompletedNCT00014638Phase 4
46Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or NotCompletedNCT01553903Phase 4
47Open Label Study of Postmenopausal Women With ER and /or PgR Positive Breast Cancer Treated With LetrozoleCompletedNCT00237224Phase 4
48The Efficacy of Prophylactic Antibiotic Administration During Breast Cancer Surgery in Overweight Patients.CompletedNCT00356148Phase 4
49Wound Infiltration and Breast Cancer SurgeryCompletedNCT01404377Phase 4
50The ODYSSEY TRIAL Phase IV Trial Evaluating the Palliative Benefit of Pamidronate or Zoledronic Acid in Breast CancerCompletedNCT01907880Phase 4

Search NIH Clinical Center for Li-Fraumeni Syndrome

Inferred drug relations via UMLS66/NDF-RT44:


Cochrane evidence based reviews: li-fraumeni syndrome

Genetic Tests for Li-Fraumeni Syndrome

About this section

Genetic tests related to Li-Fraumeni Syndrome:

id Genetic test Affiliating Genes
1 Li-Fraumeni Syndrome25 23 TP53
2 Li-Fraumeni Syndrome 125
3 Li-Fraumeni Syndrome 225
4 Abnormality of the Breast25

Anatomical Context for Li-Fraumeni Syndrome

About this section

MalaCards organs/tissues related to Li-Fraumeni Syndrome:

34
Breast, Bone, Lymph node, Brain, Lung, Testes, Prostate

Animal Models for Li-Fraumeni Syndrome or affiliated genes

About this section

MGI Mouse Phenotypes related to Li-Fraumeni Syndrome:

39 (show all 31)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00011868.9BCL2, BRCA1, CDKN2A, EGFR, MDM2, NF1
2MP:00053708.8CAV1, CDKN1A, CDKN2A, EGFR, MDM2, NF1
3MP:00053778.7BAX, BCL2, CDKN1A, EGFR, NF1, TP53
4MP:00053808.1ATM, BRCA1, BRCA2, CDKN1A, CDKN2A, EGFR
5MP:00053758.1ATM, BCL2, BRCA1, CAV1, CDKN1A, EGFR
6MP:00053857.5BCL2, BRCA1, CAV1, CDKN1A, CDKN2A, EGFR
7MP:00053717.4BAX, BRCA1, BRCA2, CDKN1A, EGFR, MDM2
8MP:00053817.4BCL2, BRCA1, BRCA2, CAV1, CDKN1A, CDKN2A
9MP:00053917.3BAX, BCL2, CDKN1A, CDKN2A, EGFR, MLH1
10MP:00053677.1BAX, BCL2, BRCA1, CAV1, CDKN1A, EGFR
11MP:00107717.0ATM, BCL2, BRCA1, BRCA2, CAV1, CDKN1A
12MP:00053696.9BAX, BCL2, BRCA1, CAV1, CDKN1A, CDKN2A
13MP:00053886.8BAX, BCL2, BRCA1, CAV1, CDKN1A, CDKN2A
14MP:00053896.5ATM, BAX, BCL2, BRCA1, BRCA2, CAV1
15MP:00036316.2ATM, BAX, BCL2, BRCA1, BRCA2, CAV1
16MP:00053906.1BAX, BRCA1, BRCA2, CAV1, CDKN1A, CDKN2A
17MP:00053865.9ATM, BAX, BCL2, BRCA1, BRCA2, CAV1
18MP:00053845.9ATM, BAX, BCL2, BRCA1, BRCA2, CAV1
19MP:00020065.9ATM, BAX, BCL2, BRCA1, BRCA2, CAV1
20MP:00053795.8ATM, BAX, BCL2, BRCA1, BRCA2, CAV1
21MP:00053975.8ATM, BAX, BCL2, BRCA1, BRCA2, CAV1
22MP:00053875.7ATM, BAX, BCL2, BRCA1, BRCA2, CAV1
23MP:00053785.4ATM, BAX, BCL2, BRCA1, BRCA2, CAV1
24MP:00107685.1ATM, BAX, BCL2, BRCA1, BRCA2, CAV1
25MP:00053764.8ATM, BAX, BCL2, BRCA1, BRCA2, CAV1

Publications for Li-Fraumeni Syndrome

About this section

Articles related to Li-Fraumeni Syndrome:

(show top 50)    (show all 242)
idTitleAuthorsYear
1
Multiple primary tumors in a family with Li-Fraumeni syndrome with a TP53 germline mutation identified by next-generation sequencing. (27516001)
2016
2
Super-Transactivation TP53 Variant in the Germline of a Family with Li-Fraumeni Syndrome. (27297285)
2016
3
The benefit and burden of cancer screening in Li-Fraumeni syndrome: a case report. (26029016)
2015
4
A functional variant in miR-605 modifies the age of onset in Li-Fraumeni syndrome. (25683625)
2015
5
Genotype Versus Phenotype: The Yin and Yang of Germline TP53 Mutations in Li-Fraumeni Syndrome. (26101242)
2015
6
Frequent occurrence of gastric cancer in Asian kindreds with Li-Fraumeni syndrome. (25318593)
2014
7
Li-Fraumeni syndrome: cancer risk assessment and clinical management. (24642672)
2014
8
EGFR-mutated lung cancer in Li-Fraumeni syndrome. (25047674)
2014
9
Heterogeneity of Li-Fraumeni syndrome links to unequal gain-of-function effects of p53 mutations. (24573247)
2014
10
Fourth primary malignant tumor in a patient with possible li-fraumeni syndrome: synchronous diagnosis of postirradiation sarcoma, cutaneous relapse of a previous soft tissue sarcoma, and lung adenocarcinoma. (25506014)
2014
11
Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome. (24706533)
2014
12
Atypical fibroxanthoma arising in a young patient with Li-Fraumeni syndrome. (24299451)
2013
13
Li-Fraumeni syndrome. (24367873)
2013
14
Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium. (22939227)
2012
15
Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. (21601526)
2011
16
Gastric cancer in individuals with Li-Fraumeni syndrome. (21552135)
2011
17
Li-fraumeni syndrome. (21779515)
2011
18
Pleomorphic carcinoma of the lung arising in a patient with Li-Fraumeni syndrome: report of a case. (21626334)
2011
19
Multiple primary cutaneous melanomas in Li-Fraumeni syndrome. (21339461)
2011
20
Familial gastric cancer and Li-Fraumeni syndrome. (19674071)
2010
21
The Li-Fraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal Fallopian tube. (19834951)
2010
22
p53+/mdm2- atypical lipomatous tumor/well-differentiated liposarcoma in young children: an early expression of Li-Fraumeni syndrome. (20028212)
2010
23
Regular surveillance for Li-Fraumeni Syndrome: advice, adherence and perceived benefits. (20658357)
2010
24
Li-Fraumeni syndrome in a Turkish family. (20426520)
2010
25
Single-cell analysis of p16(INK4a) and p21(WAF1) expression suggests distinct mechanisms of senescence in normal human and Li-Fraumeni Syndrome fibroblasts. (20039273)
2010
26
High frequency of de novo mutations in Li-Fraumeni syndrome. (19556618)
2009
27
Li-Fraumeni syndrome: the genetics and treatment considerations for the sarcoma and associated neoplasms. (19056046)
2009
28
p53 Tetramerization domain mutations: germline R342X and R342P, and somatic R337G identified in pediatric patients with Li-Fraumeni syndrome and a child with adrenocortical carcinoma. (19714490)
2009
29
Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. (18511570)
2008
30
Psychological functioning in persons considering genetic counseling and testing for Li-Fraumeni syndrome. (18688785)
2008
31
Recognition of Li Fraumeni syndrome at diagnosis of a locally advanced extremity rhabdomyosarcoma. (16534790)
2007
32
Most spontaneous tumors in a mouse model of Li-Fraumeni syndrome do not have a mutator phenotype. (16597646)
2006
33
Prenatal diagnosis in Li-Fraumeni syndrome. (15342977)
2004
34
Screening for TP53 rearrangements in families with the Li-Fraumeni syndrome reveals a complete deletion of the TP53 gene. (12584563)
2003
35
A Li-Fraumeni syndrome family with retained heterozygosity for a germline TP53 mutation in two tumors. (12885464)
2003
36
Celebrating preimplantation genetic diagnosis of p53 mutations in Li-Fraumeni syndrome. (12513881)
2001
37
Mechanism of functional inactivation of a Li-Fraumeni syndrome p53 that has a mutation outside of the DNA-binding domain. (11245491)
2001
38
Identification of a novel PTEN intronic deletion in Li-Fraumeni syndrome and its effect on RNA processing. (11120338)
2000
39
Exclusion of the genes CDKN2 and PTEN as causative gene defects in Li-Fraumeni syndrome. (10389970)
1999
40
Germline p53 mutation in a case of Li-Fraumeni syndrome presenting gastric cancer. (10645809)
1999
41
Multiple synchronous lung cancers and atypical adenomatous hyperplasia in Li-Fraumeni syndrome. (9726049)
1998
42
Exclusion of a p53 germline mutation in a classic Li-Fraumeni syndrome family. (9703430)
1998
43
Li-Fraumeni syndrome and the role of the p53 tumor suppressor gene in cancer susceptibility. (9504235)
1998
44
G2 chromosomal radiosensitivity in fibroblasts of ataxia-telangiectasia heterozygotes and a Li-Fraumeni syndrome patient with radioresistant cells. (9343108)
1997
45
Spontaneous in vitro immortalization of breast epithelial cells from a patient with Li-Fraumeni syndrome. (7799951)
1995
46
Li-Fraumeni syndrome. (7734204)
1994
47
Li-Fraumeni syndrome and germ-line mutations of the p53 gene]. (8087224)
1994
48
Several mutant p53 proteins detected in cancer-prone families with Li-Fraumeni syndrome exhibit transdominant effects on the biochemical properties of the wild-type p53. (8361758)
1993
49
Cytogenetic response to G2-phase X irradiation in relation to DNA repair and radiosensitivity in a cancer-prone family with Li-Fraumeni syndrome. (8248481)
1993
50
Follow-up study of twenty-four families with Li-Fraumeni syndrome. (1933872)
1991

Variations for Li-Fraumeni Syndrome

About this section

UniProtKB/Swiss-Prot genetic disease variations for Li-Fraumeni Syndrome:

68 (show all 84)
id Symbol AA change Variation ID SNP ID
1CHEK2p.Arg145TrpVAR_008554rs137853007
2TP53p.Met133ThrVAR_005875rs28934873
3TP53p.Ala138ProVAR_005881rs28934875
4TP53p.Cys141TyrVAR_005886
5TP53p.Pro151SerVAR_005895rs28934874
6TP53p.Pro151ThrVAR_005896
7TP53p.Pro152LeuVAR_005897
8TP53p.Arg158GlyVAR_005906
9TP53p.Arg158HisVAR_005907
10TP53p.Val173MetVAR_005926
11TP53p.Arg175GlyVAR_005929
12TP53p.Arg175LeuVAR_005930
13TP53p.Arg175HisVAR_005932rs28934578
14TP53p.His193ArgVAR_005948
15TP53p.Arg213GlnVAR_005955
16TP53p.Tyr220CysVAR_005957
17TP53p.Tyr234CysVAR_005963
18TP53p.Met237IleVAR_005965
19TP53p.Ser241PheVAR_005969rs28934573
20TP53p.Gly245CysVAR_005972
21TP53p.Gly245AspVAR_005973
22TP53p.Gly245SerVAR_005974rs28934575
23TP53p.Gly245ValVAR_005975
24TP53p.Met246ValVAR_005978
25TP53p.Arg248GlnVAR_005983rs11540652
26TP53p.Arg248TrpVAR_005984
27TP53p.Leu252ProVAR_005988
28TP53p.Glu258LysVAR_005991
29TP53p.Val272LeuVAR_005992
30TP53p.Arg273CysVAR_005993
31TP53p.Arg273GlyVAR_005994
32TP53p.Arg273HisVAR_005995rs28934576
33TP53p.Cys275TyrVAR_005998
34TP53p.Pro278LeuVAR_006003
35TP53p.Pro278SerVAR_006004
36TP53p.Pro278ThrVAR_006005
37TP53p.Arg282TrpVAR_006016rs28934574
38TP53p.Arg283CysVAR_006017
39TP53p.Glu285GlnVAR_006024
40TP53p.Glu286AlaVAR_006026
41TP53p.Pro309SerVAR_006038
42TP53p.Gly325ValVAR_006039rs28934271
43TP53p.Arg337CysVAR_006041
44TP53p.Lys292IleVAR_015819
45TP53p.Tyr163CysVAR_033035
46TP53p.Arg337HisVAR_035016
47TP53p.Arg213ProVAR_036506
48TP53p.Arg273LeuVAR_036509
49TP53p.Pro82LeuVAR_044621
50TP53p.Gly105CysVAR_044661
51TP53p.Lys132GluVAR_044740
52TP53p.Met133ArgVAR_044747
53TP53p.Ala138SerVAR_044764
54TP53p.Gln144LeuVAR_044790
55TP53p.Thr155AsnVAR_044836
56TP53p.Arg156HisVAR_044841
57TP53p.Gln167LysVAR_044885
58TP53p.Val172PheVAR_044906
59TP53p.Arg174GlyVAR_044911
60TP53p.His179TyrVAR_044939
61TP53p.Glu180LysVAR_044943
62TP53p.Arg181CysVAR_044946
63TP53p.Arg181HisVAR_044948
64TP53p.Arg196ProVAR_045007
65TP53p.Val197MetVAR_045013
66TP53p.Ser227ThrVAR_045151
67TP53p.His233AspVAR_045175
68TP53p.Asn235SerVAR_045186
69TP53p.Tyr236CysVAR_045189
70TP53p.Cys238GlyVAR_045200
71TP53p.Cys238SerVAR_045202
72TP53p.Gly244AspVAR_045232rs28934572
73TP53p.Gly244ValVAR_045236
74TP53p.Ile251MetVAR_045258
75TP53p.Leu257GlnVAR_045284rs28934577
76TP53p.Leu265ProVAR_045321
77TP53p.Arg267GlnVAR_045330
78TP53p.Arg282GlyVAR_045384
79TP53p.Arg290HisVAR_045411rs55819519
80TP53p.Arg290LeuVAR_045412
81TP53p.Arg306ProVAR_045475
82TP53p.Leu344ProVAR_045546
83TP53p.Ser241ThrVAR_047183
84TP53p.Asp281AsnVAR_047202

Clinvar genetic disease variations for Li-Fraumeni Syndrome:

5 (show all 56)
id Gene Variation Type Significance SNP ID Assembly Location
1TP53NM_000546.5(TP53): c.742C> T (p.Arg248Trp)single nucleotide variantLikely pathogenic, Pathogenicrs121912651GRCh37Chr 17, 7577539: 7577539
2TP53NM_000546.5(TP53): c.772G> A (p.Glu258Lys)single nucleotide variantPathogenicrs121912652GRCh37Chr 17, 7577509: 7577509
3TP53NM_000546.5(TP53): c.733G> T (p.Gly245Cys)single nucleotide variantPathogenicrs28934575GRCh37Chr 17, 7577548: 7577548
4TP53NM_000546.5(TP53): c.755T> C (p.Leu252Pro)single nucleotide variantPathogenicrs121912653GRCh37Chr 17, 7577526: 7577526
5TP53NM_000546.5(TP53): c.725G> A (p.Cys242Tyr)single nucleotide variantPathogenicrs121912655GRCh37Chr 17, 7577556: 7577556
6TP53NM_000546.5(TP53): c.734G> A (p.Gly245Asp)single nucleotide variantPathogenicrs121912656GRCh37Chr 17, 7577547: 7577547
7TP53NM_000546.5(TP53): c.743G> A (p.Arg248Gln)single nucleotide variantLikely pathogenic, Pathogenicrs11540652GRCh37Chr 17, 7577538: 7577538
8TP53NM_000546.5(TP53): c.398T> C (p.Met133Thr)single nucleotide variantPathogenicrs28934873GRCh37Chr 17, 7578532: 7578532
9TP53NM_000546.5(TP53): c.814G> T (p.Val272Leu)single nucleotide variantPathogenicrs121912657GRCh37Chr 17, 7577124: 7577124
10TP53TP53, 1-BP INS, 151CinsertionPathogenic
11TP53NM_000546.5(TP53): c.627_628delAA (p.Asn210Hisfs)deletionPathogenicrs587776768GRCh37Chr 17, 7578221: 7578222
12TP53NM_000546.5(TP53): c.844C> T (p.Arg282Trp)single nucleotide variantPathogenicrs28934574GRCh37Chr 17, 7577094: 7577094
13TP53NM_000546.5(TP53): c.733G> A (p.Gly245Ser)single nucleotide variantLikely pathogenic, Pathogenicrs28934575GRCh37Chr 17, 7577548: 7577548
14TP53NM_000546.5(TP53): c.818G> A (p.Arg273His)single nucleotide variantPathogenicrs28934576GRCh37Chr 17, 7577120: 7577120
15TP53NM_000546.5(TP53): c.974G> T (p.Gly325Val)single nucleotide variantPathogenicrs121912659GRCh37Chr 17, 7576872: 7576872
16TP53TP53, 1-BP DEL, CODON 257deletionPathogenic
17TP53NM_000546.5(TP53): c.524G> A (p.Arg175His)single nucleotide variantPathogenicrs28934578GRCh37Chr 17, 7578406: 7578406
18TP53NM_000546.5(TP53): c.1031T> C (p.Leu344Pro)single nucleotide variantPathogenicrs121912662GRCh37Chr 17, 7573996: 7573996
19TP53NM_000546.5(TP53): c.412G> C (p.Ala138Pro)single nucleotide variantPathogenicrs28934875GRCh37Chr 17, 7578518: 7578518
20TP53NM_000546.5(TP53): c.532delC (p.His178Thrfs)deletionPathogenicrs863223300GRCh38Chr 17, 7675080: 7675080
21TP53NM_000546.5(TP53): c.875A> T (p.Lys292Ile)single nucleotide variantPathogenicrs121912663GRCh37Chr 17, 7577063: 7577063
22TP53NM_000546.5(TP53): c.1010G> A (p.Arg337His)single nucleotide variantPathogenicrs121912664GRCh37Chr 17, 7574017: 7574017
23TP53TP53, 11-BP DEL/5-BP INSindelPathogenic
24TP53NM_000546.5(TP53): c.566C> T (p.Ala189Val)single nucleotide variantPathogenicrs121912665GRCh37Chr 17, 7578283: 7578283
25TP53NM_000546.5(TP53): c.659A> C (p.Tyr220Ser)single nucleotide variantPathogenicrs121912666GRCh37Chr 17, 7578190: 7578190
26TP53NM_000546.5(TP53): c.659A> G (p.Tyr220Cys)single nucleotide variantLikely pathogenic, Pathogenicrs121912666GRCh37Chr 17, 7578190: 7578190
27TP53NM_000546.5(TP53): c.701A> G (p.Tyr234Cys)single nucleotide variantLikely pathogenic, Pathogenicrs587780073GRCh37Chr 17, 7577580: 7577580
28TP53NM_000546.5(TP53): c.869G> A (p.Arg290His)single nucleotide variantPathogenicrs55819519GRCh37Chr 17, 7577069: 7577069
29TP53NM_000546.5(TP53): c.638G> A (p.Arg213Gln)single nucleotide variantPathogenicrs587778720GRCh37Chr 17, 7578211: 7578211
30PIK3CANM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys)single nucleotide variantPathogenicrs104886003GRCh37Chr 3, 178936091: 178936091
31TP53NM_000546.5(TP53): c.766A> G (p.Thr256Ala)single nucleotide variantLikely pathogenicrs587781433GRCh37Chr 17, 7577515: 7577515
32TP53NM_000546.5(TP53): c.1101-2A> Gsingle nucleotide variantLikely pathogenic, Pathogenicrs587781664GRCh37Chr 17, 7573010: 7573010
33TP53NM_000546.5(TP53): c.473G> A (p.Arg158His)single nucleotide variantLikely pathogenic, Pathogenicrs587782144GRCh37Chr 17, 7578457: 7578457
34TP53NM_000546.5(TP53): c.916C> T (p.Arg306Ter)single nucleotide variantPathogenicrs121913344GRCh37Chr 17, 7577022: 7577022
35TP53NM_000546.5(TP53): c.542G> A (p.Arg181His)single nucleotide variantLikely pathogenic, Pathogenicrs397514495GRCh38Chr 17, 7675070: 7675070
36TP53NM_000546.5(TP53): c.455C> T (p.Pro152Leu)single nucleotide variantPathogenicrs587782705GRCh38Chr 17, 7675157: 7675157
37TP53NM_000546.5(TP53): c.267delC (p.Ser90Profs)deletionLikely pathogenicrs587783062GRCh38Chr 17, 7676102: 7676102
38TP53NM_001126115.1(TP53): c.318T> G (p.Cys106Trp)single nucleotide variantPathogenicrs193920789GRCh38Chr 17, 7674249: 7674249
39TP53NM_000546.5(TP53): c.375G> A (p.Thr125=)single nucleotide variantPathogenicrs55863639GRCh37Chr 17, 7579312: 7579312
40TP53NM_000546.5(TP53): c.709A> G (p.Met237Val)single nucleotide variantPathogenicrs730882004GRCh38Chr 17, 7674254: 7674254
41TP53NM_000546.5(TP53): c.824G> A (p.Cys275Tyr)single nucleotide variantLikely pathogenic, Pathogenicrs863224451GRCh38Chr 17, 7673796: 7673796
42TP53NM_000546.5(TP53): c.584T> C (p.Ile195Thr)single nucleotide variantPathogenicrs760043106GRCh38Chr 17, 7674947: 7674947
43TP53NM_000546.5(TP53): c.672+1G> Asingle nucleotide variantPathogenicrs863224499GRCh38Chr 17, 7674858: 7674858
44TP53NM_000546.5(TP53): c.973G> T (p.Gly325Ter)single nucleotide variantPathogenicrs863224500GRCh37Chr 17, 7576873: 7576873
45TP53NM_000546.5(TP53): c.273G> A (p.Trp91Ter)single nucleotide variantPathogenicrs876660548GRCh37Chr 17, 7579414: 7579414
46TP53NM_000546.5(TP53): c.-202-?_*1207+?deldeletionPathogenic
47TP53NM_000546.5(TP53): c.662delA (p.Glu221Glyfs)deletionPathogenicrs878854071GRCh38Chr 17, 7674869: 7674869
48TP53NM_000546.5(TP53): c.673-1G> Tsingle nucleotide variantPathogenicrs878854073GRCh37Chr 17, 7577609: 7577609
49TP53NM_000546.5(TP53): c.845G> A (p.Arg282Gln)single nucleotide variantPathogenicrs730882008GRCh38Chr 17, 7673775: 7673775
50TP53NM_000546.5(TP53): c.586C> T (p.Arg196Ter)single nucleotide variantPathogenicrs397516435GRCh37Chr 17, 7578263: 7578263
51TP53NM_000546.5(TP53): c.637C> T (p.Arg213Ter)single nucleotide variantPathogenicrs397516436GRCh37Chr 17, 7578212: 7578212
52TP53NM_000546.5(TP53): c.817C> T (p.Arg273Cys)single nucleotide variantLikely pathogenic, Pathogenicrs121913343GRCh37Chr 17, 7577121: 7577121
53CHEK2CHEK2, 1-BP DEL, 1100CdeletionPathogenic, risk factor
54CHEK2NM_007194.3(CHEK2): c.470T> C (p.Ile157Thr)single nucleotide variantLikely pathogenic, Pathogenic, risk factorrs17879961GRCh37Chr 22, 29121087: 29121087
55CHEK2NM_007194.3(CHEK2): c.433C> T (p.Arg145Trp)single nucleotide variantLikely pathogenic, Pathogenicrs137853007GRCh37Chr 22, 29121242: 29121242
56CHEK2CHEK2, 1-BP DEL, 1422TdeletionPathogenic

Cosmic variations for Li-Fraumeni Syndrome:

8 (show top 50)    (show all 58)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM564NRASsoft tissue,striated muscle,rhabdomyosarcoma,NSc.35G>Ap.G12D0
2COSM496HRASsoft tissue,striated muscle,rhabdomyosarcoma,NSc.181C>Ap.Q61K0
3COSM1745010MYOD1soft tissue,striated muscle,rhabdomyosarcoma,NSc.365T>Gp.L122R0
4COSM5692CTNNB1soft tissue,striated muscle,rhabdomyosarcoma,NSc.134C>Ap.S45Y0
5COSM553KRASsoft tissue,striated muscle,rhabdomyosarcoma,NSc.182A>Tp.Q61L0
6COSM763PIK3CAsoft tissue,striated muscle,rhabdomyosarcoma,NSc.1633G>Ap.E545K0
7COSM580NRASsoft tissue,striated muscle,rhabdomyosarcoma,NSc.181C>Ap.Q61K0
8COSM486HRASsoft tissue,striated muscle,rhabdomyosarcoma,NSc.37G>Cp.G13R0
9COSM12475CDKN2Asoft tissue,striated muscle,rhabdomyosarcoma,NSc.238C>Tp.R80*0
10COSM584NRASsoft tissue,striated muscle,rhabdomyosarcoma,NSc.182A>Gp.Q61R0
11COSM13014PTPN11soft tissue,striated muscle,rhabdomyosarcoma,NSc.214G>Ap.A72T0
12COSM45255TP53soft tissue,striated muscle,rhabdomyosarcoma,NSc.668C>Gp.P223R0
13COSM11081TP53soft tissue,striated muscle,rhabdomyosarcoma,NSc.733G>Tp.G245C0
14COSM5664CTNNB1soft tissue,striated muscle,rhabdomyosarcoma,NSc.121A>Gp.T41A0
15COSM562NRASsoft tissue,striated muscle,rhabdomyosarcoma,NSc.34G>Tp.G12C0
16COSM476BRAFsoft tissue,striated muscle,rhabdomyosarcoma,NSc.1799T>Ap.V600E0
17COSM775PIK3CAsoft tissue,striated muscle,rhabdomyosarcoma,NSc.3140A>Gp.H1047R0
18COSM10660TP53soft tissue,striated muscle,rhabdomyosarcoma,NSc.818G>Ap.R273H0
19COSM766PIK3CAsoft tissue,striated muscle,rhabdomyosarcoma,NSc.1636C>Ap.Q546K0
20COSM393242DICER1soft tissue,striated muscle,rhabdomyosarcoma,NSc.2062C>Tp.R688*0
21COSM760PIK3CAsoft tissue,striated muscle,rhabdomyosarcoma,NSc.1624G>Ap.E542K0
22COSM13016PTPN11soft tissue,striated muscle,rhabdomyosarcoma,NSc.226G>Cp.E76Q0
23COSM521KRASsoft tissue,striated muscle,rhabdomyosarcoma,NSc.35G>Ap.G12D0
24COSM585NRASsoft tissue,striated muscle,rhabdomyosarcoma,NSc.183A>Tp.Q61H0
25COSM516KRASsoft tissue,striated muscle,rhabdomyosarcoma,NSc.34G>Tp.G12C0
26COSM483HRASsoft tissue,striated muscle,rhabdomyosarcoma,NSc.35G>Tp.G12V0
27COSM1651691ALKsoft tissue,striated muscle,rhabdomyosarcoma,NSc.3830T>Cp.I1277T0
28COSM569NRASsoft tissue,striated muscle,rhabdomyosarcoma,NSc.37G>Cp.G13R0
29COSM959251DICER1soft tissue,striated muscle,rhabdomyosarcoma,NSc.5113G>Ap.E1705K0
30COSM13013PTPN11soft tissue,striated muscle,rhabdomyosarcoma,NSc.205G>Ap.E69K0
31COSM4169595DICER1soft tissue,striated muscle,rhabdomyosarcoma,NSc.5425G>Ap.G1809R0
32COSM522KRASsoft tissue,striated muscle,rhabdomyosarcoma,NSc.35G>Cp.G12A0
33COSM3738549DICER1soft tissue,striated muscle,rhabdomyosarcoma,NSc.5365-1G>Tp.?0
34COSM45005TP53soft tissue,striated muscle,rhabdomyosarcoma,NSc.739A>Gp.N247D0
35COSM3738451DICER1soft tissue,striated muscle,rhabdomyosarcoma,NSc.5439G>Tp.E1813D0
36COSM532KRASsoft tissue,striated muscle,rhabdomyosarcoma,NSc.38G>Ap.G13D0
37COSM1235326PIK3CAsoft tissue,striated muscle,rhabdomyosarcoma,NSc.3023C>Tp.S1008F0
38COSM762PIK3CAsoft tissue,striated muscle,rhabdomyosarcoma,NSc.1625A>Tp.E542V0
39COSM14271PTPN11soft tissue,striated muscle,rhabdomyosarcoma,NSc.1508G>Tp.G503V0
40COSM45256TP53soft tissue,striated muscle,rhabdomyosarcoma,NSc.871A>Cp.K291Q0
41COSM959249DICER1soft tissue,striated muscle,rhabdomyosarcoma,NSc.5125G>Ap.D1709N0
42COSM10813TP53soft tissue,striated muscle,rhabdomyosarcoma,NSc.394A>Gp.K132E0
43COSM528KRASsoft tissue,striated muscle,rhabdomyosarcoma,NSc.37G>Ap.G13S0
44COSM563NRASsoft tissue,striated muscle,rhabdomyosarcoma,NSc.34G>Ap.G12S0
45COSM480HRASsoft tissue,striated muscle,rhabdomyosarcoma,NSc.34G>Ap.G12S0
46COSM3744763DICER1soft tissue,striated muscle,rhabdomyosarcoma,NSc.5428G>Tp.D1810Y0
47COSM3738459DICER1soft tissue,striated muscle,rhabdomyosarcoma,NSc.5437G>Ap.E1813K0
48COSM44536TP53soft tissue,striated muscle,rhabdomyosarcoma,NSc.728T>Cp.M243T0
49COSM575NRASsoft tissue,skin,sarcoma,NSc.38G>Cp.G13A0
50COSM45253TP53soft tissue,striated muscle,rhabdomyosarcoma,NSc.611A>Gp.E204G0

Copy number variations for Li-Fraumeni Syndrome from CNVD:

6
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
111639317650000010700000Copy numberTP53Li-fraumeni syndrome
21179911775058217531588DeletionTP53Li-fraumeni syndrome
31181091775717207590863Copy numberTP53Li-fraumeni syndrome
4162983222350000025900000Copy numberLi-fraumeni syndrome

Expression for genes affiliated with Li-Fraumeni Syndrome

About this section
Search GEO for disease gene expression data for Li-Fraumeni Syndrome.

Pathways for genes affiliated with Li-Fraumeni Syndrome

About this section

Pathways related to Li-Fraumeni Syndrome according to GeneCards Suite gene sharing:

(show top 50)    (show all 86)
idSuper pathwaysScoreTop Affiliating Genes
19.8ATM, BRCA1, TP53
2
Show member pathways
9.6ATM, CHEK2, MDM2, TP53
39.5ATM, BRCA1, CDKN1A, TP53
4
Show member pathways
9.4ATM, BRCA1, BRCA2, CHEK2, TP53
5
Show member pathways
9.4ATM, CDKN2A, CHEK2, MDM2, TP53
69.3CDKN1A, CDKN2A, EGFR, MDM2, TP53
7
Show member pathways
9.3CDKN1A, EGFR, MDM2, PTEN, TP53
8
Show member pathways
9.3CDKN1A, EGFR, MDM2, PIK3CA, TP53
99.2BCL2, CDKN1A, MDM2, PIK3CA, TP53
109.1ATM, BRCA1, CDKN1A, CHEK2, MDM2, TP53
11
Show member pathways
9.1ATM, BRCA1, CDKN1A, CHEK2, MDM2, TP53
12
Show member pathways
9.1ATM, BRCA1, CDKN1A, CHEK2, MDM2, TP53
139.1ATM, CDKN1A, CDKN2A, CHEK2, MDM2, TP53
149.0BAX, CDKN1A, MDM2, TP53
159.0BCL2, CDKN1A, CDKN2A, MDM2, PTEN, TP53
16
Show member pathways
8.9ATM, CDKN1A, EGFR, MDM2, PIK3CA, PTEN
17
Show member pathways
8.9ATM, BRCA1, BRCA2, CDKN1A, CHEK2, MDM2
188.9ATM, BCL2, CDKN1A, CDKN2A, MDM2, TP53
198.9EGFR, IDH1, PIK3CA, PTEN, TP53
20
Show member pathways
8.8BRCA2, CDKN1A, CDKN2A, EGFR, MDM2, PIK3CA
218.8CAV1, CDKN1A, EGFR, MDM2, PIK3CA, TP53
228.8ATM, BAX, BCL2, CHEK2
238.8BRCA1, CAV1, CDKN1A, EGFR, MDM2, PTEN
248.7CDKN1A, CDKN2A, EGFR, MDM2, NF1, PTEN
25
Show member pathways
8.7CAV1, CDKN1A, EGFR, MDM2, PIK3CA, PTEN
268.6BAX, CDKN1A, EGFR, MLH1, TP53
278.6ATM, BRCA1, CDKN1A, CDKN2A, CHEK2, MDM2
288.6BAX, BCL2, PIK3CA, PTEN, TP53
298.5BAX, CDKN1A, CDKN2A, MDM2, PIK3CA, TP53
30
Show member pathways
8.5BAX, CDKN1A, MDM2, PIK3CA, PTEN, TP53
318.4BCL2, BRCA1, CDKN1A, EGFR, MDM2, PIK3CA
328.2ATM, BAX, CDKN1A, CDKN2A, CHEK2, PIK3CA
33
Show member pathways
8.2BAX, BCL2, BRCA1, CDKN1A, EGFR, PIK3CA
348.1ATM, BAX, BCL2, CDKN1A, CDKN2A, MDM2
35
Show member pathways
8.1ATM, BAX, BCL2, CDKN2A, MDM2, PIK3CA
367.9ATM, BCL2, BRCA1, CDKN1A, CDKN2A, EGFR
37
Show member pathways
7.8ATM, BAX, BRCA1, CDKN1A, CDKN2A, CHEK2
38
Show member pathways
7.8ATM, BAX, BCL2, CDKN1A, CDKN2A, MDM2
39
Show member pathways
7.8ATM, BAX, BCL2, CHEK2, EGFR, MDM2
40
Show member pathways
7.7ATM, BAX, BCL2, BRCA1, CDKN1A, CHEK2
41
Show member pathways
7.6ATM, BAX, BCL2, BRCA1, CHEK2, MDM2
42
Show member pathways
7.5ATM, BAX, BRCA1, CDKN1A, CDKN2A, CHEK2
43
Show member pathways
7.5BAX, BCL2, CDKN1A, EGFR, MDM2, MLH1
44
Show member pathways
7.3ATM, BCL2, BRCA1, BRCA2, CDKN1A, CDKN2A
45
Show member pathways
7.3ATM, BAX, BCL2, CDKN1A, CDKN2A, CHEK2
467.2BAX, BCL2, CAV1, CDKN1A, EGFR, MDM2
477.1ATM, BAX, BCL2, BRCA1, BRCA2, CHEK2
487.1BAX, BCL2, BRCA2, CDKN1A, CDKN2A, EGFR
496.9ATM, BAX, BCL2, BRCA1, BRCA2, CDKN1A
50
Show member pathways
6.8ATM, BAX, BCL2, BRCA1, CDKN1A, CDKN2A

GO Terms for genes affiliated with Li-Fraumeni Syndrome

About this section

Cellular components related to Li-Fraumeni Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1pore complexGO:004693010.0BAX, BCL2
2protein complexGO:00432349.5BRCA1, BRCA2, CAV1, MDM2, TP53
3cytosolGO:00058296.3BAX, BCL2, CAV1, CDKN1A, CDKN2A, IDH1
4nucleusGO:00056346.3ATM, BAX, BCL2, BRCA1, BRCA2, CDKN1A

Biological processes related to Li-Fraumeni Syndrome according to GeneCards Suite gene sharing:

(show top 50)    (show all 60)
idNameGO IDScoreTop Affiliating Genes
1chromosome breakageGO:003105210.7BRCA1, BRCA2
2chordate embryonic developmentGO:004300910.7BRCA1, BRCA2
3DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorGO:000697810.5BRCA1, BRCA2, TP53
4response to X-rayGO:001016510.5BRCA2, CDKN1A, TP53
5phosphatidylinositol biosynthetic processGO:000666110.4CDS1, PIK3CA, PTEN
6double-strand break repairGO:000630210.4BRCA1, BRCA2, CHEK2
7intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorGO:004277110.4BRCA2, CDKN1A, TP53
8strand displacementGO:000073210.2ATM, BRCA1, BRCA2
9DNA synthesis involved in DNA repairGO:000073110.2ATM, BRCA1, BRCA2
10negative regulation of G1/S transition of mitotic cell cycleGO:200013410.2BCL2, CDKN1A, PTEN
11double-strand break repair via nonhomologous end joiningGO:000630310.2ATM, BRCA1, MLH1
12cellular senescenceGO:009039810.1CAV1, CDKN1A, CDKN2A
13cell agingGO:000756910.1BCL2, BRCA2, TP53
14cell cycle arrestGO:000705010.0ATM, CDKN1A, CDKN2A, TP53
15regulation of nitrogen utilizationGO:00068089.9BAX, BCL2
16positive regulation of developmental pigmentationGO:00480879.9BAX, BCL2
17replicative senescenceGO:00903999.9ATM, CDKN1A, CDKN2A, CHEK2, TP53
18leukocyte homeostasisGO:00017769.9BAX, BCL2
19negative regulation of anoikisGO:20008119.9BCL2, CAV1, PIK3CA
20negative regulation of cell growthGO:00303089.9BCL2, CDKN1A, CDKN2A, TP53
21regulation of signal transduction by p53 class mediatorGO:19017969.8ATM, BRCA1, CHEK2, MDM2, TP53
22response to estradiolGO:00323559.8BRCA1, BRCA2, EGFR, PTEN
23response to nutrientGO:00075849.8BRCA1, BRCA2, CAV1, PTEN
24regulation of protein heterodimerization activityGO:00434979.8BAX, BCL2
25cellular response to hypoxiaGO:00714569.7BCL2, MDM2, PTEN, TP53
26intrinsic apoptotic signaling pathwayGO:00971939.7BAX, CDKN1A, TP53
27negative regulation of fibroblast proliferationGO:00481479.7BAX, NF1, TP53
28Ras protein signal transductionGO:00072659.7CDKN1A, CDKN2A, NF1, TP53
29cellular response to organic substanceGO:00713109.6BAX, BCL2, MDM2
30regulation of gene expressionGO:00104689.6BCL2, MDM2, NF1, PIK3CA
31response to organic cyclic compoundGO:00140709.5CDKN1A, EGFR, IDH1, PTEN
32response to ionizing radiationGO:00102129.5ATM, BAX, BRCA1
33neuron apoptotic processGO:00514029.4ATM, BAX, BCL2
34extrinsic apoptotic signaling pathway via death domain receptorsGO:00086259.4BAX, BCL2, NF1
35positive regulation of neuron apoptotic processGO:00435259.4ATM, BAX, NF1, TP53
36response to steroid hormoneGO:00485459.2BCL2, IDH1, MDM2
37negative regulation of apoptotic processGO:00430669.2BCL2, CDKN1A, EGFR, MDM2, PTEN, TP53
38DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestGO:00069779.1ATM, BAX, CDKN1A, CHEK2, MDM2, TP53
39regulation of apoptotic processGO:00429819.0ATM, BAX, BCL2, BRCA1, TP53
40positive regulation of apoptotic processGO:00430659.0ATM, BAX, NF1, PTEN, TP53
41positive regulation of intrinsic apoptotic signaling pathwayGO:20012448.9BAX, BCL2, CAV1, TP53
42response to toxic substanceGO:00096368.9BAX, BCL2, CDKN1A, MDM2
43regulation of cell cycleGO:00517268.8ATM, BAX, BCL2, CDKN1A, PTEN
44response to gamma radiationGO:00103328.7BAX, BCL2, BRCA2, CAV1, CHEK2, TP53
45intrinsic apoptotic signaling pathway in response to DNA damageGO:00086308.6ATM, BAX, BCL2, BRCA1, BRCA2, CHEK2
46cell proliferationGO:00082838.6BAX, BCL2, BRCA2, EGFR, PTEN, TP53
47apoptotic processGO:00069158.2ATM, BAX, BCL2, BRCA1, CHEK2, PTEN
48cellular response to DNA damage stimulusGO:00069748.1ATM, BAX, BCL2, BRCA1, BRCA2, CDKN1A
49response to drugGO:00424937.7BAX, BCL2, CAV1, CDKN1A, MDM2, PTEN
50negative regulation of cell proliferationGO:00082857.6BAX, BCL2, CAV1, CDKN1A, CDKN2A, NF1

Molecular functions related to Li-Fraumeni Syndrome according to GeneCards Suite gene sharing:

(show all 8)
idNameGO IDScoreTop Affiliating Genes
1cyclin-dependent protein serine/threonine kinase inhibitor activityGO:000486110.6CDKN1A, CDKN2A
2BH3 domain bindingGO:00514349.9BAX, BCL2
3protein phosphatase bindingGO:00199039.8BCL2, EGFR, TP53
4enzyme bindingGO:00198999.0BRCA1, CAV1, EGFR, MDM2, PTEN, TP53
5ubiquitin protein ligase bindingGO:00316259.0BCL2, BRCA1, CDKN1A, CHEK2, EGFR, MDM2
6protein kinase bindingGO:00199019.0CAV1, CDKN2A, CHEK2, EGFR, PTEN, TP53
7protein heterodimerization activityGO:00469828.2BAX, BCL2, CAV1, EGFR, TP53
8identical protein bindingGO:00428027.6BAX, BCL2, CAV1, CHEK2, EGFR, MDM2

Sources for Li-Fraumeni Syndrome

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
25GTR
26HGMD
27HMDB
28ICD10
29ICD10 via Orphanet
30ICD9CM
31IUPHAR
32KEGG
35MedGen
37MeSH
38MESH via Orphanet
39MGI
42NCI
43NCIt
44NDF-RT
47NINDS
48Novoseek
50OMIM
51OMIM via Orphanet
55PubMed
56QIAGEN
61SNOMED-CT via Orphanet
65Tumor Gene Family of Databases
66UMLS
67UMLS via Orphanet